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Background: The presence of human milk banks allows the use of pasteurised donated breast 
milk in Neonatal Intensive Care Units (NICUs), which has been shown to have benefits for 
preterm infant recipients. There is, however, limited research on moderate to late (320 to 366 
week) preterm infants as a NICU population. The use of a human milk analyser allows human 
milk banks to determine the nutrient composition of donated breast milk, which could further 
help improve the nutritional and growth status of infants through individualised fortification 
procedures. 
Objectives: This study was in two phases: Phase one – to determine the macronutrient (fat, 
protein, carbohydrate), and energy content of donor breast milk from the Human Milk Bank, 
NICU, Christchurch Women’s Hospital; the impact that pasteurisation or maternal 
characteristics – such as gestational age or sex of the donor’s infant, lactation weeks of the 
donor, or whether the donor’s infant was currently preterm or term; and whether nutritional 
labelling of milk could help with individualised fortification procedures. 
Phase two – to compare the nutritional status of moderate to late preterm infants (320 
to 366 weeks) in the NICU at Christchurch Women’s Hospital prior to the Neonatal Human 
Donor Milk Bank opening (i.e. 2013) with matched donor milk recipient infants born after 
donor milk became available (i.e. 2016/2017), with respect to: demographics, nutrition 
interventions, and nutrition and growth outcomes. 
Design: Phase one was an observational milk analysis study, using a human milk analyser to 
analyse 63 samples of donor breast milk from 27 donor mothers. Phase two was a 
retrospective comparison audit of 71 matched pairs of moderate to late (320 to 366 week) 
preterm infants from two cohorts, matched by gestational age, sex and twin status. 
Results: For phase one, donated breast milk samples showed a wide variation in the 
concentration of energy and macronutrients. There was a significant (p≤0.001) but small 
(≤3%) difference between pre- and post-pasteurisation samples of donated breast milk for 
energy, fat and total carbohydrate. The main impact of maternal characteristics was the 
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lactation weeks of the donor and whether the milk was term, which were both significantly 
inversely associated with protein concentration (both p<0.001). For phase two, there was a 
significant increase in the percentage of infants who were exclusively breast milk fed in the 
NICU (p<0.001), from 27% to 72%, and an increase in breastfeeding discharge rates from 
21% to 40%, when donor breast milk was available. In the first week of life, energy and fat 
intakes were significantly greater for donor milk recipients by 4.9kcal/kg/day and 0.6g/kg/day 
respectively. 
Conclusion: There is a large variation in the energy and macronutrient composition of breast 
milk donated by New Zealand women. This is very useful to know in order to tailor 
fortification of pasteurised donor milk for preterm NICU infants. These results also suggest 
that the use of pasteurised donor breast milk in the Christchurch NICU may be responsible for 
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1 Introduction  
 
Worldwide, there are an estimated 14.9 million preterm births per year (more than 1 in 10 
total births (1)). The birth rate of preterm infants for New Zealand is 7.4% of total births 
(which is averaged over 10 years (2)). Prematurity stages are: extreme (<316/7 weeks); 
moderate (320/7– 336/7 weeks (3)); and late (340/7 - 366/7 weeks (4)). Research looking at 
moderate to late preterm infants is not as extensive as that looking at extreme prematurity, 
with recent New Zealand research focusing on the earlier preterm gestation (5). However, 
moderate to late preterm gestations make up the largest proportion of total preterm births (6, 
7). Worldwide, over 80% of total preterm births are moderate to late preterm gestation (1). 
This is also the case for both New Zealand (2) and Australia (8).   
Breast milk is the optimum nutrition for preterm infants due to its nutritional and 
immunological make up. Breast milk is highly variable with many factors influencing its 
composition, including both maternal and infant characteristics (9-18). The infant’s own 
mother’s milk should be the first choice, with lactation promotion vital in increasing breast-
feeding rates (19). However, if mother’s milk is not available, pasteurised donor milk is the 
preferred choice before infant formula is considered (19). The use of pasteurised donor milk 
for preterm infants has not only been seen to reduce the risk of necrotising enterocolitis (20-
23), but it also reduces the use of infant formula (19, 24, 25), and potentially may increase 
breastfeeding rates on discharge (26). Currently, rates of exclusive breastfeeding for New 
Zealand infants in general are relatively low. In 2017, only 52% of infants were exclusively 
breastfed at 6 weeks of age, further declining to 21% by 6 months (27).  
The presence of human milk banks in neonatal units has given premature infants 
access to breast milk (28, 29), even if their mother is not able to provide it. The main 
problems with providing donor milk to premature infants is that the pasteurisation process 
leads to the loss of important immunological components (30-36), and the majority of donor 
milk is mature term milk (37), and therefore low in protein and unable to meet the 
requirements of the preterm infant. Thus, fortification is required for donor milk. The use of a 
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human milk analyser in human milk banks enables donor milk composition to be determined. 
It is useful knowing compositional variation between breast milk samples, so potentially 
tailored fortification procedures for infants could be implemented (38). There is, however, a 
lack of standardised breast milk compositional data (39) and reference methods (40) used for 
analysis of human milk, and limited information on the nutrient composition of breast milk 
from New Zealand women (41). This makes it challenging to compare and conduct neonatal 
research (39), as well as to determine the nutritional intake of preterm infants who are 
receiving breast milk. There is certainly very little research on the impact of donor breast milk 
on the nutrition and health of moderate to late preterm infants in neonatal intensive care.   
The sole official Human Milk Bank in New Zealand, based in the Neonatal Intensive 
Care Unit (NICU) at Christchurch Women’s Hospital, recently purchased a Human Milk 
Analyser. The current study is the first study in New Zealand to analyse the composition of 
donor breast milk using a human milk analyser. It is also vital to determine whether the 
availability of donor milk since the opening of the Human Milk Bank has improved 
nutritional status for infants, in particular moderate to late preterm infants as they are the 






2 Literature Review 
 
This chapter provides an overview of moderate to late preterm infants, particularly with 
respect to feeding and nutrition, and growth and nutrition requirements; breast milk 
composition and benefits; human milk banks; and human milk processing and feeding.  
2.1 Preterm infants 
The definition of a preterm infant is an infant born before the end of the 37th week of 
pregnancy (42), most accurately determined from an ultrasound scan (43). The three stages of 
prematurity are extreme (<316/7 weeks); moderate (320/7– 336/7 weeks (3)); and late (340/7 - 
366/7 weeks (4)). The earlier the prematurity of birth is, the greater the risk of morbidity and 
mortality (44).  
2.1.1 Moderate to late preterm infants  
Moderate to late preterm infants make up the largest proportion of total preterm births, but 
there is limited research on infants of this gestational age (4, 7). Breastfeeding late preterm 
infants has been seen to have significant challenges, especially feeding difficulties (45). 
Preterm infants require tube feeding until they are about 35 – 37 weeks of age due to their 
immature suck-swallow-breathe pattern (46). This is usually done through bolus feeding but 
some infants require continuous feeding. If an infant has been tube feeding for a long period 
or been ill, it may be challenging changing to nipple feeding, by breast or bottle (46). There is 
also a lower prevalence of exclusive breastfeeding seen for mothers of late preterm infants in 
the first week of life (47), and by six weeks, compared to term infants (48). Milk expression 
support for mothers by nursing staff has been highlighted to make a difference in increasing 
rates of exclusive breastfeeding for late preterm infants after discharge (45, 49, 50). Late 
preterm infants are often a similar size and weight to term babies, so their development is 
often assumed to be mature, and they are considered to be at lower risk for morbidity 
compared to earlier stages (4). However, because of their immature systems, late preterm 
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infants are still at a much higher risk of short-term and long-term complications and mortality 
than term babies (4). These are outlined in Table 2.1 below.  
 
Table 2.1: Short-term and long-term complications for moderate to late preterm infants 
Length of 
time 
      Complications  
Short term - Higher risk of developing hypoglycaemia (4) and hypothermia if they are 
unable to properly transition between the intra and extrauterine environments 
(51). 
- Prolonged jaundice (4, 51) 
- Respiratory distress (i.e. apnoea) (4) 
- Gastrointestinal dysfunction (4, 51) 
- Development of Sudden Infant Death Syndrome (SIDS) – a two-fold higher 
risk than term babies (51). 
- A less developed suck swallow reflex which can lead to difficulties in 
successful breastfeeding by mothers (4, 51). 
Long-term into 
adulthood 
- Visual problems (44) 
- Poorer cognition (44) - born at a time when brain growth is rapid (51, 52). 
- Learning difficulties –problems at school and developmental delays higher 
than in children born at term (53-59). 
 
2.2 Growth and nutrition requirements of the moderate to late preterm infant 
2.2.1 Monitoring of growth  
For all infants, weight, length and head circumference measurements are taken and recorded 
on growth charts to monitor growth over time (60). After birth, all babies experience some 
loss of weight. Subsequent weight gain for a preterm infant if over 2kg is 25 – 30g/kg/day, or 
if under 2kg, 15 – 20g/kg/day. Length measurements can be more indicative of growth than 
weight, but can be difficult to obtain (60). Currently, the three standardised growth charts 
health practitioners and researchers use are UK-WHO, INTERGROWTH, and Fenton 2013. 
UK-WHO is an older data set based on a smaller sample size, whereas, the INTERGROWTH 
21st study has the most recent data available, and very consistent growth standards, however is 
not suitable for babies born moderate preterm or earlier. In order to make future neonatal 
research standardised, Cormack et al. (39) have recommended the use of Fenton 2013 charts 
(61), and reporting growth as z-scores. The definition of a z-score is “the number of standard 
deviation (SD) away from the mean, when the distribution is normal” (62). A negative z-score 
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represents a measure below the reference population mean of 0.00, and a positive value 
represents a measure above the reference population mean (62). It is important to note that 
caution should be applied when considering whether it is safe and realistic to achieve perfect 
growth on preterm growth charts.  Short- and long-term risks such as necrotising enterocolitis 
(NEC) and risk of higher adiposity and obesity in childhood (63-65) have been associated 
with intense feeding and maximising growth trajectories.  
2.2.2 Nutritional Requirements 
The European Society for Paediatric Gastroenterology, Hepatology, and Nutrition Committee 
(ESPGHAN) have recommended guidelines for the nutrient requirements of preterm infants 
weighing less than 1800g (66) (Table 2.2).  For a more detailed table on nutrient 










Charted weight data for gestational age indicates that moderate preterm (320 – 336 weeks) 
average weights are 1700 – 1900g (67). This is an indication that these nutrient intakes may 
be applicable for some infants born moderately preterm but not for late preterm infants. 
Research into late preterm nutrient requirements is more limited, with dated and less detailed 
recommendations available (68), reinforcing the fact there are no current requirements set for 
late preterm infants.  
2.3 Breast milk composition  
Breast milk is a complex substance which supplies the critical nutritional components for the 
growth and nutrition of a term infant for the first six months after birth (14). Breast milk is 
produced in three stages: colostrum, transitional and mature milk. In the first few days 
Table 2.2: Energy and macronutrient recommendations for enteral 
feeding (ESPGHAN guidelines) 
Nutrient Per kg/day 
Energy, kcal 110 – 135 
Protein, g [<1 kg body weight] 4.0 – 4.5  
Protein, g [1 – 1.8 kg body weight] 3.5 – 4.0 
Lipids, g 4.8 – 6.6 
Carbohydrate, g 11.6 – 13.2 
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postpartum (generally 1 – 5 days (10, 69)), 2 – 20ml of thick yellow colostrum is produced 
per feed (10). Transitional milk occurs after colostrum and before mature milk, the latter 
established at about 14 days postpartum (10). The average production of milk is 
approximately 750 – 800ml per day during exclusive breastfeeding (70). Research looking at 
the composition of breast milk has found significant differences in the nutritional and 
immunological components between individual women, lactation stage and duration, and 
whether the infant is preterm or term. This will be discussed further in the sections below.   
2.3.1 Macronutrient composition of breast milk 
Breast milk contains a number of carbohydrate, protein and fat components. The main 
carbohydrate components found in breast milk are lactose and oligosaccharides (20%) (71, 
72). There are more than 100 types of oligosaccharides identified to date (73); the role of 
which will be discussed below in Section 2.3.3. Lactose concentrations are low in colostrum 
however they increase with the transition to mature milk (10). Whether there are differences 
in the carbohydrate composition of preterm and term milks is unclear (74-78). The main types 
of protein in breast milk are whey and casein (79). Protein levels are higher in colostrum and 
subsequently reduce in mature milk (10). Furthermore, protein levels are seen to be higher in 
preterm milk than term milk (11-13, 75, 77, 78, 80). There are over 200 fatty acids in breast 
milk, contributing to about 50% of infant energy intake (81, 82). Long chain polyunsaturated 
fatty acids in milk have been linked to infant growth and brain development (83), however 
concentrations of omega 3 fatty acids such as docosahexaenoic acid in breast milk is highly 
influenced by maternal diet (84). Therefore, it has been suggested that if the diet is low in 
long-chain polyunsaturated fatty acids (for instance if fatty fish is not eaten (83, 84)) mothers 
should consider supplementation (79, 85, 86). Like lactose, fat concentrations are low in 
colostrum and increase with the transition to mature milk. Whether there are differences in fat 
concentrations between preterm and term milks is also unclear (74, 75, 77, 78, 84, 85). For 




2.3.2 Micronutrient composition of breast milk 
Concentrations of fat-soluble vitamins A, E and the majority of minerals in breast milk, are 
highest in colostrum, and decrease with increasing duration of lactation (10, 79, 87, 88). This 
is in contrast to water-soluble vitamins, where concentrations are lowest in colostrum and 
subsequently increase with lactation duration (10). There are small differences seen with 
certain water-soluble vitamins between preterm and term milks (89). For further details, refer 






Table 2.3: Macronutrient composition of breast milk 




glucose, galactose)  
 
 
- Lactose low in colostrum. 
- Increase with change to 




- Most studies report lower 
lactose levels in preterm milk 
vs term milk but that they both 
increase with lactation stage 
(74-76). 
- However, one study has 
reported higher lactose in 
preterm milk (77), and another 





(urea, creatinine, amino 
acids)) (79) 
 
- Highest in colostrum (10-13). 
- Decreases in transitional and 
mature milks (10, 11). 
 
- Higher in preterm milk than 






- Low in colostrum. 
- Increase with change to 
transitional and mature milk 
(10). 
 
- Most studies report no 
difference seen between 
preterm and term milk (78, 84, 
85). 
- However two studies reported 
higher fat in preterm milk (75, 
77), and another saw a lower 




Table 2.4: Micronutrient composition of breast milk 
Micronutrients Lactation stage and composition Preterm vs term milk 
Fat soluble vitamins  
(A, D, E, K) 
 
 
- A and E high in colostrum which decreases 
with transitional and mature milks  
(from 400 – 600 IU/dL to 60 – 200 IU/dL 
and from ~1.0mg/dL to 0.2 – 0.3mg/dL 
respectively (10, 87)). 
- D low in breast milk, more so with lack of 
maternal sun exposure (79). 
- K low in breast milk, stable with changing 
milk stages. Infant injection at birth 
required (79). 
 
- Preterm milk vitamin A 













- All (except B12) low in colostrum and 
increase in concentrations in transitional 
milk (10, 89). 
- B12 higher in colostrum, declines with 
increased lactation duration (89). 
 
- Thiamin and Pyridoxine 
higher in term milk than 
preterm milk (89). 
- B12, pantothenic acid 
and vitamin C higher in 
preterm milk than term 
milk (89). 
- Content of riboflavin, 
niacin, folate and biotin 
similar between preterm 








trace elements)  
 
- Minerals present in higher concentration in 
colostrum than mature milk (10). 
- Zinc highest in colostrum which declines 
with lactation stage (from 5.4mg/L to ~1-
2mg/L in mature milk (88)). 
- Magnesium, sodium and chloride high in 
colostrum (79). 
- Potassium and calcium lower in colostrum 
compared to mature milk (79). 
 
- Magnesium and iron 
higher in preterm milk. 
(78). 
- Calcium same in both 
(78). 
- Phosphorus lower in 
preterm milk than term. 
(78). 
 
2.3.3 Immunological components of breast milk 
The main immunological components in breast milk are: immunoglobulins (e.g. IgA, sIgA, 
IgG, IgM), oligosaccharides, growth factors and lactoferrin, with enzymes, hormones, 
cytokines and cells also playing an important role. Infants have an immature immune system 
at birth so immunoglobulins in breast milk provide the infant with protection against infection 
(82). The concentrations of these are highest in colostrum, reflecting this lactation stage as the 
highest immunoprotective stage for the infant from pathogenic activity (10, 82). Furthermore, 
concentrations of immunological components are higher in preterm milk compared to term 
milk (12, 13, 76). Oligosaccharides are prebiotics, which along with other microbes (90) help 
populate and maintain a healthy gut microflora and protect against pathogens through growth 
9 
 
inhibition (73, 91-93). The concentration of oligosaccharides is highest in colostrum and 
preterm milk (76). The protective effect of breast milk against diarrhoea and infections is 
thought to be partly due to the presence of these oligosaccharides (22, 71, 93). Additionally, 
oligosaccharides, cytokines and growth factors may be associated with the prevention of a 
serious gastrointestinal inflammation disorder for newborns (35, 94), necrotising enterocolitis 
(NEC), through assisting in the development of a healthy gut microflora (29, 95). Further 
details of these components and their concentrations in breast milk can be seen in Table 2.5 
below.  
Table 2.5: Immunological components and concentrations in breast milk 
Immunological 
Components 
Lactation stage and composition Preterm vs term milk 
Growth Factors - Growth Factors (e.g. Epidermal 
growth factor; EGF) higher in 
colostrum than mature milk (79, 
82). 
- Higher EGF in preterm vs term 
milk (79). 
Immunoglobulins (IgA, 
sIgA, IgG, IgM) (79) 
 
- All immunoglobulins highest in 
colostrum (79). 
- sIgA higher in colostrum than 
mature milk (from 12mg/ml to 
1mg/ml (10, 82)). 
- IgM and lysozyme 
concentrations similar in 
preterm and term milk (12). 
- IgA in colostrum higher in all 
preterm milk (13). 
Human Milk 
Oligosaccharides  
- Highest in colostrum dropping in 
mature milk (from 20-23g/L to 
13g/L (76)). 
- Higher in preterm milk than 
term milk (76). 
Lactoferrin - Rich in colostrum (79, 96). - Lactoferrin higher in preterm 
milk than term milk (96). 
Abbreviations: EGF – Epidermal Growth Factor, Ig – Immunoglobulins, sIgA – secretory immunoglobulin A 
 
2.3.4 Current breast milk compositional data  
Researchers looking at the composition of breast milk have produced a variety of 
compositional figures. Due to the high variation in the composition of breast milk, it is 
difficult to determine reference values for breast milk composition. Two studies – Boyce et al. 
(97) and Cormack et al. (39) – have produced preterm composition data which could be used 
for calculations in future research and the development of evidence-based guidelines. There 
are composition values for term breast milk (i.e. Gidrewicz et al. (9)), however no term 





Table 2.6: Selected compositional data for preterm and term breast milk from three reviews 
Study  Preterm vs term Milk type  Macronutrients 








Boyce et al. (97) 2016 
Systematic 
literature review 
Preterm milk Week 1 57.11 1.9 2.59 6.55 or 5.66 
 Week 2 – 8 65.6 1.27 3.46 7.34 or 6.15 




Preterm milk Transitional 65 1.5 - - 
 Mature 72 1.2 - - 





Preterm milk Colostrum (day 1 – 3) 49 2.7 2.2 5.1 
 Week 1 (mean) 61 2.2 2.6 5.7 
 Mature (week 5 – 12) 73 1.1 3.3 6.2 
Term milk Colostrum (day 1 – 3) 54 2.0 1.8 5.6 
 Week 1 (mean) 60 1.8 2.2 5.8 




2.3.5 Factors affecting composition  
The nutritional composition of breast milk is influenced by a wide variety of factors relating 
to the mother, baby and characteristics of feeding. These include maternal age and diet; sex 
and gestation of the infant; mode of delivery; lactation stage (colostrum, transitional, mature 
milk); duration of the breastfeed, and tube feeding (10-18, 74-76, 81, 82, 87, 89, 96, 98-100). 
Breastfed infants get a diet which varies in its macronutrient content over the course of 
a few months. Fat is the most highly variable nutrient in breast milk. It varies over the 
lactation period (increasing over time), within one feed (increases with longer feeding time 
(70)), maternal age (potentially diet influenced (15, 16)), and tube feeding method (the 
preferred method being bolus feeding due to there being no significant fat loss (100, 101)). 
Healthy term infants fed breast milk, should adequately meet their requirements, if maternal 
diet is adequate or if maternal nutrient supplementation continues throughout the lactation 
period (79, 87). Maternal diet is not a predictor of macronutrient composition but can affect 
the levels of micronutrients in the milk, with maternal deficiencies increasing the risk of 
infant deficiencies, particularly in the preterm infant (14, 87-89). For further details, refer to 




Table 2.7: Maternal, infant and processing characteristics which have an effect on the energy and macronutrients of breast milk 
Characteristic Energy Fat (total, saturated, 
unsaturated) 
Carbohydrate (lactose) Protein Comments 
Maternal Age      
- Fat profile thought to 
have some dietary 
influence (15, 81, 83) 
but could be metabolic 
differences (16) 
Older Mothers  
>35-37 (15, 16) 
 - Higher fat in colostrum and 
transitional milk 
- Lower saturated fat profile to 
unsaturated fats 
- Lactose content higher in 
mature milk with increased 
maternal age (15) 
 
Younger mothers  
<35 -37 (15, 16) 
 - Lower fat in colostrum and 
milk (98). Higher 
polyunsaturated fat (i.e. 
Omega 6) content 
- Lower lactose in colostrum 
and milk 
 
Maternal Ethnicity  
(NZ European, Māori, 
Pacific, Asian) (41) 
 - No differences in total fat 
between ethnicities.   
- Significant difference for 
polyunsaturated fats: highest 
levels with Asian mothers 
- No difference between 
ethnicities 
- No difference 
between 
ethnicities  
- Polyunsaturated fats 
positively associated 
with dietary intake 
Maternal Diet  - Not effected (14) but quality 
of fatty acids does influence 
infants stores (81)  i.e. 
docosahexaenoic acid dose 
dependent relationship (102) 
- Not effected even in cases 
of extreme malnutrition 
(81) 
 - Maternal diet is not a 
predictor of 
macronutrient 
composition (14, 87-89) 
Maternal BMI 
(98) 






- Protein is the only 
macronutrient affected 









Characteristic Energy Fat (total, saturated, 
unsaturated) 
Carbohydrate (lactose) Protein Comments 
Sex of baby      
Female - Lower calorie 
milk (17) 
 - Lower carbohydrate 
content (17) 
 - Women carrying male 
infants consume 10% 
more total energy 
during pregnancy (103) 
- Male infants consume 
~10% more milk than 
females (18). 
Male - 25% higher 
calorie content of 
milk (18) 
 - Higher carbohydrate 
content (17) 
 
Birth length (Long) 
(17) 
- Lower calorie 
content 
- Lower fat in milk    
Mode of delivery 
(Caesarean compared 
to vaginal) 
- No difference in 
calorie content 
(17) 
- Higher fat in milk (17) - Lower carbohydrate (17) - Lower protein in 
colostrum (99) 
- Differences may be due 
to hormonal changes 
throughout contractions 
and labour (99) 
Time of delivery      
Preterm   - Lower lactose (74-76) - Higher protein 
(11-13, 75, 77, 
78, 80) 
- Postnatal age and 
gestational stage 
predictors of breast milk 
content (9) Term   - Higher lactose - Lower protein 
Tube feeding methods 
for preterm infants 
     
 
- Intermittent bolus 
feeding is considered the 
preferred feeding 
method.  
- The Holter infusion 






 - Loss of fat (70) – 47.4% total 
fat loss due to particle 




 - Lost 16.8% fat content (un-
homogenised milk) (101) 
  
Intermittent bolus  - No significant fat loss (70)   
Holter Infusion 
pump 
 - Large fat bolus delivery end at 
feed (100) 
  




Characteristic Energy Fat (total, saturated, 
unsaturated) 
Carbohydrate (lactose) Protein Comments 
Lactation Stage      






 - Higher in fat - Higher in lactose - Lower in 
protein 
 
Feeding length      
- Average 67% milk 
available consumed 
each feed meaning 
infants stopping part 
way may consume less 
fat from hind milk (104) 
Fore milk (81)  - Low fat content - High lactose  
Hind milk (14, 74, 
82) 
 - Higher fat content - Lower lactose  
Processing effects  
(for donor milk) 
     
Holder 
Pasteurisation 
 - No significant effect on fatty 
acids. Reduction seen for total 
fat (105-108) 






Freezing  - Reduction due to fat 
hydrolysis (111-113) 















Table 2.8: Maternal, infant and processing characteristics which have an effect on the micronutrients and immunological components in breast milk 
Characteristic Vitamins Minerals  Immunological Comments 
Maternal Ethnicity 
(NZ European, Māori, 
Pacific, Asian (41)) 
 
 - Magnesium levels of NZ 
European mothers higher 
than Māori and Pacific 
mothers. 
- No difference for calcium, 
zinc or selenium  
 - High magnesium for NZ 
Europeans were not 
significantly associated 
with dietary intake.  
Maternal Diet - Deficiencies of Thiamin, 
Riboflavin, Niacin, pyridoxine, 
Folate, B12, Pantothenic Acid, 
D, E and A result in low levels 
in breast milk increasing risk of 
infant deficiency (14, 87, 89) 
- Mothers status for 
Selenium, iodine and severe 
iron anaemia - deficiencies 
reflect infant stores (14, 88) 
 - Maternal diet does 
influence micronutrient 
composition (14, 87-89). 
Sex of baby     
Male   - Lower lactoferrin 
concentrations in mature milk 
(96) 
 
Mode of delivery 
(Caesarean compared to 
vaginal) 
  - Significant differences in 
microbes in colostrum -impact 
on infants’ microbiota (90) 
- Differences may be due 
to hormonal changes 
throughout contractions 
and labour (90) 
Twin pregnancy   - Higher lactoferrin in colostrum 
(96) 
 
Time of delivery     
Preterm - B12, pantothenic acid and C 
higher (89) 
- Magnesium and iron higher, 
phosphorus lower (78) 
- Growth factors, IgA,IgG, 
oligosaccharides and lactoferrin 
higher content (13, 76, 79, 96) 
 
Term - Thiamin and pyridoxine higher 
(89) 
   
 
 




Characteristic Vitamins Minerals  Immunological Comments 
Lactation Stage     
Colostrum  
(10-13) 
- A, E, B12 levels high 
- Low levels of Thiamin, 
Riboflavin, Niacin, pyridoxine, 
Pantothenic Acid, Biotin, 
Folate, C  
- Magnesium, sodium and 
chloride, zinc higher  




- A, E, B12 lower 
- Increased levels of Thiamin, 
Riboflavin, Niacin, pyridoxine, 
Pantothenic Acid, Biotin, 
Folate, C 
- Potassium and calcium 
higher  
- Immunoglobulins decrease in 
concentration 
 
Processing effects  
(for donor milk) 
    
Holder Pasteurisation - Decline seen with vitamins 
particularly C and E (36, 114-
116) 
- No effect seen (109, 117) - Reduction in 
immunoglobulins, lactoferrin 






2.4 Benefits of breast milk 
Breast milk provides optimum nutrition, as it enables infants to benefit from the well-
established health benefits which are both short term and lifelong. Breast milk is protective 
against infections due to the presence of host defence factors i.e. sIgA, lactoferrin, 
oligosaccharides, cytokines and immunoglobulins, which prevent the growth of pathogens in 
the gastrointestinal and respiratory tracts (28). The feeding of breast milk improves feed 
tolerance and fat absorption, which is vital as preterm infants have lower enzyme levels 
compared to term infants (29). The available evidence suggests that breast milk has a role in 
neurodevelopment, with breastfed toddlers and children having a higher cognitive function, 
however a confounder may be maternal socioeconomic status and IQ (28). There is also the 
potential for breast milk to influence the risk reduction of long-term conditions such as 
obesity. For further details, see Table 2.9 below. 
Table 2.9: Benefits of breast milk for preterm infants  
Factor Evidence of benefit 
Infection prevention - Acute otitis media (ear infection) risk halved for 
exclusively breast milk fed infants (28) 
- Lower risk of necrotising enterocolitis (19, 29, 95) 
Feeding tolerance - Faster transition through the gut improves stool 
frequency (29) 
- Improves feeding tolerance (29) 
- Reduces amount of time to achieve full enteral feeds (37) 
- Improved fat absorption by lipase and milk enzymes (29) 
Potential role in neurodevelopment - Increased cognitive function and IQ (28, 119) 
Potential long-term effects - Lower blood pressure (28) 
- Lower blood cholesterol (28) 
- Lower risk for type 2 diabetes (28) 
- Lower risk of obesity (63, 120, 121) 
 
2.5 Historical perspectives on infant feeding with non-maternal breast milk 
Infant feeding practices differ within and between cultures, and throughout civilisation. The 
act of feeding another’s baby with one’s milk is not a new concept and historically there have 
been two well established feeding methods which have distinct social and cultural differences: 
wet nursing and cross feeding (122). Wet nursing, as quoted by Stevens (123), can be defined 




historically, the earliest recorded date being 2000 BC (123). In comparison, cross feeding is 
the informal sharing of breastfeeding amongst known women (124), without the legal 
obligation of reciprocity as in the case of wet nurses (122). Cross feeding was a practice seen 
in indigenous populations in Australia, Islamic cultures (124), and pre-European New 
Zealand Māori (125). Reduction of breastfeeding rates as a result of the introduction of 
artificial infant formula in the 19th century was seen among New Zealand Māori populations, 
from a combination of poor Māori health and the influence of early European practices (125). 
The result of this can still be seen today, with Māori breastfeeding rates 14% lower than 
European rates up to seven months of age (126, 127).  
2.5.1 Formalised human milk banks  
Human milk banks were established to provide pasteurised donated breast milk to preterm 
and term infants whose mother’s milk was insufficient. This originated first in Vienna in 1909 
and in Boston in 1919 (128). Human milk banks have standards applied to donors which 
include screening for specific viral infections and testing for bacterial growth to minimise the 
exposure to donor milk recipients (108, 129). It is important to note that the presence of 
bacteria, which naturally occurs on the nipple flora of breasts, is not a concern in milk direct 
from mother to her own baby (130), however it is essential to eradicate this bacteria in 
donated milk (131). Pump or manual expression of milk is the only acceptable milk collection 
method as it maintains a higher fat content and volume compared to drip milk (129). Drip 
milk is defined as “milk which spontaneously drips from the contralateral breast during the 
suckling of an infant” (132). It in turn has a lower caloric content through fat loss, and 
although adequate for the mother’s own baby in the short-term, is not allowed for donor milk 
(132). There are now approximately 654 established human milk banks worldwide (133), the 
majority situated in Europe (206 in 25 countries) and South America (258 in 9 countries). In 
New Zealand, the Neonatal Intensive Care Unit in Christchurch Women’s Hospital opened 
the first human milk bank (134) in 2014, and it remains the only official human milk bank in 




2.5.2 Evidence for the use of pasteurised donor milk 
As discussed above in Sections 2.3 and 2.4, the nutritional and immunological properties of 
breast milk and its benefits are the reasons why donated breast milk for preterm infants is of 
such importance to health professionals and mothers. Donor milk allows mothers to give their 
baby breast milk if they do not have the ability to provide their own; reduces the use of infant 
formula (24), especially within the first two weeks after birth (19, 25); and significantly 
reduces the incidence of NEC for extremely premature infants if exclusive breast milk feeding 
is achieved (20-23). In 85% of cases, NEC occurs in infants <32 weeks’ gestation, therefore it 
is less common for moderate to late preterm infants to develop NEC, however this still 
remains a risk (135). It has also been seen that the increased use of donor milk does not 
displace the mother’s provision of her own milk (25). Although research on the medical 
effects of pasteurised donor milk is limited, there is some indication that the use of donor milk 
from a human milk bank is unlikely to pose a threat to breastfeeding rates, (19, 136) and may 
encourage an increase in breastfeeding rates for a longer period of time after discharge (26). 
There are challenges associated with giving donor milk to preterm infants. The majority of 
donor milk provided is mature term milk (37), composition of which is lower in protein than 
preterm milk composition, and in addition, donor milk has a highly variable composition (37). 
The donor’s diet can influence the micronutrient composition of the milk, which could lead to 
nutrient deficiencies if not corrected (14, 87-89), and there are the effects of processes such as 
pasteurisation, which can impact on the immunological and nutritional composition of the 
donor breast milk. 
2.6 Processing effects on breast milk composition  
2.6.1 Holder Pasteurisation 
The main procedure used for human milk pasteurisation is Holder pasteurisation. It is the 
most widely used procedure and is currently recommended for human milk banks (137). Also 
known as low temperature, long time (LTLT) pasteurisation, it is a thermal processing 




involves placing the product in a 62.5oC water bath, that is held for 30 minutes at constant 
temperature (131). After pasteurisation, the product is rapidly cooled down to -10oC, and then 
frozen at -20oC for storage (131). Pasteurisation in human milk banks is essential to ensure 
microbial safety of the donated milk by destroying pathogens that are present (131). Holder 
pasteurisation is successful at eradicating bacteria such as E. coli, salmonella, C. diphtheria, 
S. aureus and viruses like polio, rotavirus, herpes simplex, influenza and cytomegalovirus 
(CMV) (131, 138, 139). For information on alternate pasteurisation methods (e.g. High 
temperature, short time; and High-pressure processing) and their effects on breast milk 
composition, see Appendix B.   
2.6.1.1 Effect of Holder pasteurisation on breast milk composition  
Holder pasteurisation is unlikely to have an effect on the energy or protein content of breast 
milk, according to the majority of research reported (Table 2.10). There is no evidence that 
Holder pasteurisation has a significant effect on carbohydrate and fatty acids (110, 140). 
Water soluble vitamins are more heat sensitive, especially vitamin C, with no conclusive 
results seen for fat soluble vitamins, in particular vitamin E. Conclusions cannot be drawn 
about growth factors or cytokines due to the limited studies, but different types of cytokines 
and growth factors can withstand a variety of temperatures. While total protein content is not 
affected, specific protein components such as immunoglobulins, lysozyme and lactoferrin are 
significantly decreased, confirming that the main concern about Holder pasteurisation is the 
loss of immunological components (110). The beneficial components which remain post 
pasteurisation however (both immunological and nutritional), still have health advantages 
over infant formula (37). There is now the ability to restore important bacteria lost in 
pasteurised donor milk by the addition of a small quantity of mother’s own breast milk (as 
individual mothers’ milk has a unique microbiota (141)). This new research suggests a new 
avenue for restoring and further increasing the immunological benefits of breast milk post 
pasteurisation, which will further improve the microbiota of the developing infant (141). For 











significant reduction Did not observe an effect 
Energy (107)  (105, 110) 
Macronutrients 
Protein  
Total protein (12, 106) (105, 109, 139, 142, 
143) 
(110) 
Total Nitrogen   (107, 108) 
Fat 
Total fat (105-108) (109, 111, 118, 140)  
Fatty Acids:  
    Saturated 
  
(36, 111, 115, 118, 140) 
 
(111, 115, 118, 140) 
       Monounsaturated  (36, 115, 140) (36, 111, 115, 118, 140) 
       Polyunsaturated  (36, 115, 140) (35, 36, 111, 115, 118, 140) 
Total carbohydrate 
Lactose   (32, 106, 107, 109) 
Oligosaccharides   (144, 145) 
Micronutrients 
Vitamins 
A (146) (109, 116)  
D (147)  (116) 
E/tocopherols  
   (12-46% reduction) 
(36, 115) (114) (116) 
C  
  (16- 36% reduction) 
(114-116)  (148) 




  (148) 
Pyridoxine   
  (15% reduction) 
(116)  (148) 
B12   (116, 148, 149) 
Folic Acid  
  (31% reduction) 








  (Reduction 20-62%) 
(30-34)  
 
(12, 149-151)  
IgM 
  (Reduction 50-100%) 
(30, 32, 33) (12, 149)  
IgG 
  (Reduction 23-100%) 
(30) (12, 33, 149, 151)  
Lactoferrin 
     (Reduction 35-90%) 
 (33, 149, 151)   
Lysozyme (31) (12, 151) (34, 149) 
Growth Factors  (35)  (32) 











2.6.2 Other processing effects on breast milk composition  
There are inconclusive findings for the effect of freezing at -20oC on the energy and 
macronutrient content of breast milk (107, 152). Again, fat is seen to be the most variable 
nutrient in breast milk, with fat hydrolysis seen to occur at -20oC temperature (111-113), but 
not at -70oC (111, 112). The repeated freezing and thawing of milk samples leads to fat loss, 
and feeding of unhomogenised milk, induces up to 34% fat loss (106). Homogenisation is a 
process recognised to preserve fat content and it is recommended to homogenise milk before 
giving it to infants, enabling increased absorption rates (26). Ultrasonic homogenisation is 
seen to have the least effect on fat content as milk globules are altered to a similar size as in 
cow’s milk (101). Freezing breast milk does not appear to significantly change enzymes and 
immunological components (151). Other impacts on the nutritional and immunological 
components in breast milk include: storage time and temperature, tube feeding, light and 
microwave thawing and heating, and container type. For more details on these, refer to 
Appendix C.  
2.7 Analysis testing of pasteurised donor milk 
Analysis of human milk can be done using a Human Milk Analyser (HMA). This method has 
been developed in Sweden by Miris and requires 3ml of milk for analysis (40). This device 
uses mid – infrared transmission spectroscopy and involves a thin film of the sample being 
exposed to infrared radiation, producing a series of transmitted wavelengths correlating to the 
different components in the sample (153). There are currently no standardised reference 
methods used for measuring the macronutrient profile of human milk (38). The HMA has 
input human milk standards based on reference methods for measuring the macronutrients fat, 
protein and total carbohydrate (154). For the Miris HMA’s these are: the Rose-Gottlieb 
method for fat, the Kjeldahl method for protein, and the oven drying method for carbohydrate 
(calculated by difference from total solids (155)). Research looking at the effectiveness of the 
HMA to measure milk composition accurately, emphasises the need for machine calibration 




A recent review looking at the current research on human milk analysers has 
concluded that the differences seen between studies may be the result of the numerous 
reference methods available for use; the characteristic and size of the sample set; and 
preparation procedures (including the importance of pre-analysis homogenisation, to improve 
fat measurement accuracy (38)). In choosing a homogeniser, an Ultrasonic Processor will 
produce highly accurate readings for fat, lactose, energy and nitrogen (97). Interestingly, a 
number of studies have found that the results determined using the HMA did not match 
results using reference methods (153, 154, 156, 157). This may be due to the lack of human 
milk standardisation reference methods (40). Mid-infrared analysers have been used for 
decades in the dairy industry but have since been adapted for human milk. Many of the 
currently available reference methods were therefore used for the analysis of cow’s milk, 
including in the first studies analysing human milk (158). The main problem is inaccurate 
protein measures, due to differences in the non-protein nitrogen content between human and 
cow milks (159). In human milk, non-protein nitrogen accounts for 24% of total nitrogen, 
therefore only 76% of total nitrogen is from protein (160). Moreover, most bedside human 
milk analysers are calibrated assuming that 100% of total nitrogen is from protein, which 
means true protein HMA readings may be overestimated (160). More recently, Miris have 
released an updated calibration control kit in January 2018 (161). This calibration control 
validates the internal calibration of the machine, which was initially determined by reference 
methods chosen by the manufacturer. This new Miris control kit includes two controls – the 
first corresponding to average concentrations of the macronutrients in breast milk and the 
second corresponding to concentrations of macronutrients closer to the high end of the HMA 
measuring range (162). These are believed to improve the accuracy of the Miris 
measurements of breast milk composition. 
2.8 Differences between infants fed breast milk or infant formula  
The most common milk base for infant formula is cow’s milk, which due to its complex 




content of formula is much higher than is necessary for infants, with ongoing research looking 
at reducing these levels and making it closer to the concentration seen in breast milk (81). 
Components which are not naturally found in infant formula include the vast array of 
immunological components (i.e. immunoglobulins, enzymes, growth factors, hormones, and 
oligosaccharides (81, 82, 92)). Research looking into medical outcomes, growth and 
neurodevelopment have seen differences between infants fed donor breast milk (fortified or 
not), and infant formula. Formula fed infants have a higher risk of feeding intolerance and a 
double the risk of developing NEC compared to those fed donor breast milk (163, 164), but 
have a higher rate of growth and weight gain than infants fed donor breast milk (although this 
is slightly improved with breast milk fortification (165, 166)). Recent research has raised 
concern that faster growth in infancy (due to over feeding and higher protein levels) may be 
increasing the risk of obesity (63-65), and as such the benefits of fortified human milk 
outweigh a poorer growth rate (165). For further details, see Table 2.11 below. 
 
2.9 Fortification of donor breast milk 
Human milk fortifier (HMF) has become a popular way of increasing the nutrient profile of 
donated breast milk for preterm infants, because the consequence of using unfortified donor 
breast milk (and mother’s own) may be a slower growth rate (19). As the nutritional 
composition of donor breast milk is determined by a variety of factors (the main being the 
donor’s lactation stage and duration), donor breast milk alone may not be enough to meet 
requirements, especially for protein and energy which are essential for growth. 
Supplementation solely with energy or with any one macronutrient is not recommended (46, 
Table 2.11: Differences seen between infants fed donor breast milk or formula milk 
Measure Donor Breast milk Infant formula  
Neurodevelopmental Scores No difference (163), Poorer (167) No difference (163) 
All-cause mortality No difference (163) No difference (163) 
Necrotising Enterocolitis Lower risk (163) Higher risk (163) 
Feeding Intolerance Lower risk (163) Higher risk (163) 
Weight Gain Lower (163, 167) Higher (163) 
Length Lower (163) Higher (163) 




168), as deficiencies could arise from not meeting other nutrient targets. There are a variety of 
human milk fortifiers available for use in neonatal units, the protein base being derived from 
cow’s milk (169). Two reviews concluded breast milk fortifiers were beneficial for short term 
growth (166, 170), however, it is important that supplementation of breast milk with a 
fortifier only be considered if toleration of milk volume and growth are not adequate (60).  
2.9.1 Individual fortification 
The most common breast milk fortifying practice is standard fortification, which assumes a 
single composition for all breast milk and therefore prescribes a fixed dose of the fortifier 
(171). More recently, individual fortification, in which protein, carbohydrate and fat are 
matched with the individual infant’s requirements, has been used. The two proposed methods 
for individual fortification are: targeted fortification, which is the process of analysing the 
breast milk each infant receives and fortifying to meet macronutrient needs on an individual 
basis; and adjustable fortification, which uses measurements of blood urea nitrogen to 
indicate the infant’s current protein needs. Research (mainly on low birth weight <1.5kg 
preterm infants) has shown the success of individualised fortification for weight and growth 
improvements during hospital stay (168, 171-174). Furthermore, individual fortification of 
breast milk after HMA analysis enables milk to be closer to nutrient recommendations (38) 
and by improving the nutrition and growth of preterm infants, this could lead to a reduction in 
the risk of long-term problems (171). Despite the success seen with individual fortification, it 
has been noted that standard fortification may be just as adequate as targeted fortification 
(173), due to individualised fortification being time consuming, labour intensive, and 
requiring expensive equipment (171, 173), and growth differences have not been seen by 
other researchers (173, 175). Breast milk related initiatives such as human milk banks, 
standard fortification, and more recently individualised fortification of breast milk, have led to 
improvements in preterm growth velocity (176).  
2.10 Summary and identification of the research gap  




immunological components allowing protection against infections, and may reduce risk of 
future diseases. The use of pasteurised donated breast milk for preterm infants gives health 
benefits but, in most cases, fortification is required due to variation in milk composition. This 
variability is influenced by factors including maternal and infant characteristics, and 
processing effects such as pasteurisation. Holder pasteurisation is the recommended method 
for human milk banks, and although it results in a loss of some important immunological 
factors, the remaining nutritional and immunological components are of vital benefit for a 
preterm infant. Concern around a slower growth rate of preterm infants fed donor breast milk 
compared to formula fed infants has led to increased protein levels, but this may have 
subsequently led to overfeeding through the maximisation of infant growth trajectories. 
Research now highlights that fast growth and high protein levels may be increasing the risk of 
increased adiposity in infancy, and future obesity (63-65). Thus, efforts should be made to 
encourage the use of pasteurised donor breast milk over infant formula, if available, and the 
expectation that increased growth will occur along the infant’s individual birth centile. The 
use of a human milk analyser to determine the composition of breast milk plays an important 
role in understanding the variation between donated breast milk samples, and this may enable 
better fortification procedures. Moderate to late preterm infants make up the majority of 
preterm births but there is currently limited research on their nutritional management, no up to 
date standardised nutritional recommendations for moderate preterm infants, and no 
nutritional requirements set for late preterm infants. Without these guidelines, it is very 
difficult to know whether these infants are being provided with their nutrient requirements. 
What this study will add: As has been discussed above, little is known of the nutrient 
composition of New Zealand women’s breast milk, and therefore of donated breast milk in 
particular. In addition, there is limited research on the nutrition of moderate to late preterm 
infants, as well as the impact on their nutritional and growth outcomes of having access to 





3 Objective Statement 
 
The aim of this study was to determine the nutrient composition of donated breast milk, and 
whether the use of donor breast milk provided by the Human Milk Bank at Christchurch 
Women’s Hospital (New Zealand’s sole operating breast milk bank) has improved the 
nutritional status of moderate to late preterm infants (320 to 366 weeks’ gestation) in the 
Neonatal Intensive Care Unit at Christchurch Women’s Hospital. The specific aims and 
objectives of the two phases of the study were:  
 
Phase One - Donor Breast Milk Analysis 
Aim: To determine the nutritional composition of donor breast milk from the Human Milk 
Bank at Christchurch Woman’s Hospital using a human milk analyser, and whether 
composition was influenced by pasteurisation or maternal characteristics such as gestational 
age or sex of the donor’s infant, lactation weeks of the donor, or whether the donor’s infant 
was currently preterm or term. 
Objectives: 
- To determine the macronutrient (fat, protein, carbohydrate) and energy content of 
human donor breast milk from the Human Milk Bank at Christchurch Women’s 
Hospital.  
- To determine the impact of pasteurisation on the macronutrient and energy content of 
donated breast milk. 
- To determine the role that the maternal characteristics – gestational age and sex of the 
donor’s infant, lactation weeks of the donor, and whether the donor’s infant was 
currently preterm or term – have on breast milk composition.  
- To determine whether nutritional labelling of pasteurised donor milk based on 
maternal characteristics could help guide selective fortification of pasteurised donor 




- To compare the breast milk nutrient values from the literature that were used to 
estimate nutrient intakes in phase two, with actual breast milk nutrient values from 
phase one. 
Phase Two -Retrospective Nutrition and Growth Audit 
Aim: To determine the impact of donor breast milk on the nutrition of moderate to late 
preterm infants (320 to 366 weeks’ gestation) in the Neonatal Intensive Care Unit at 
Christchurch Women’s Hospital.  
Objectives: To compare moderate to late preterm infants (320 to 366 weeks) in the Neonatal 
Intensive Care Unit at Christchurch Women’s Hospital prior to the milk bank opening (i.e. 
2013) with matched donor milk recipient infant born after donor milk became available (i.e. 
2016/2017), with respect to:  
- Demographic characteristics (sex; delivery mode; gestational age at birth and 
discharge from Neonatal Intensive Care Unit; presence of necrotising enterocolitis; 
and mean length of stay in the Neonatal Intensive Care Unit). 
- Nutrition interventions (length of time and number of intravenous nutrition 
interventions; time to and type of first enteral feed; the number of days to reach full 
enteral feeds; number exclusively having breast milk throughout their stay in the 
Neonatal Intensive Care Unit; use of infant formula, human milk fortifier and 
additional macronutrient additives).  
- Nutritional outcomes (daily intake of energy, fat, protein and carbohydrate; lowest 
plasma urea, albumin and sodium concentrations during stay; type and method of 
nutrition at discharge including breastfeeding rates). 
- Growth outcomes (weight, length and head circumference values with respective z-
scores at birth and discharge; number of days to regain birth weight; and z-score 





4 Subjects and Methods 
 
4.1 Study design 
This study was in two phases. Phase one was an observational milk analysis study, which 
looked at the composition of donor breast milk and the effect pasteurisation and maternal 
characteristics have on the energy and macronutrient concentration of donor breast milk. 
Phase two was a retrospective comparison audit looking at differences in nutritional 
interventions, outcomes and growth between two cohorts of moderate to late (320 to 366 
week) preterm infants who were inpatients of the Neonatal Intensive Care Unit – a 2013 
cohort who were inpatients before the Human Milk Bank opened, and a 2016/17 cohort who 
were recipients of donor breast milk after the Human Milk Bank opened.  
4.2 Phase One – Donor Breast Milk Analysis 
4.2.1 Human Milk Bank processes 
The Neonatal Human Donor Milk Bank in the Neonatal Intensive Care Unit (NICU) at 
Christchurch Women’s Hospital (referred to as the “Human Milk Bank” in this thesis) was 
opened in 2014. Detailed processes were informed by the NICE guidelines for the operation 
of donor milk bank services (177). The following is a summary of the processes carried out 
by the Human Milk Bank – for more details, refer to Appendix E.  
Potential donors require two stages of screening to become a registered donor. Women 
from the community, or NICU, are screened with the following exclusion criteria applied to 
each donor: smoker; regularly consumes alcohol (defined as exceeding 1-2 units once or 
twice a week); uses recreational drugs; positive for HIV, hepatitis B or C, HTLV I/II; 
syphilis; exposure to passive smoke; medication use; environmental or chemical exposure, 
blood infusion in the past four months; travelled to countries at risk of communicable 
diseases; lived in UK/France between 1980-1996; or has had recent infections.  
Raw milk is frozen at -18°C to -20°C for a maximum of six months after it has been 
expressed and is then thawed for a maximum of 24 hours at 2 – 6°C before pasteurisation. 




these batches of pooled milk are from individual donors, not a mix of milk from several 
donors. Pooled raw milk is swirled in the jug and decanted into 250ml bottles for 
pasteurisation. Containers (Sterifeed, UK) used for the milk are Bisphenol A (BPA) free, 
suitable for freezing and pasteurisation, sterile and comply to food standards, as noted by 
company regulations (Medicare Colgate, England) (178-181). Microbial tests on raw milk are 
performed routinely, with a sample from each batch of milk tested for bacterial contamination 
including Enterobacteriaceae, and Staphylococcus aureus. Donated breast milk is pasteurised 
by the Holder Pasteurisation method (refer to Section 2.6.1), using a Sterifeed pasteuriser 
(Sterifeed, UK) and is usually performed up to two days a week by the Human Milk Bank 
Assistant. All milk is then decanted into smaller quantities (200, 100, 50ml bottles) for use in 
the NICU and stored in the freezer for up to 3 months. Hygiene precautions – i.e. good hand 
hygiene and use of gloves, are undertaken including during pasteurisation and whenever 
handling donor milk.  
There is a prioritisation process for infants to be recipients of pasteurised donor milk 
and this is outlined in Figure 4.1. It is determined by the current supply and demand. The 
colours represent the availability of donor milk, and the appropriate colour at the time is 
displayed outside the Human Milk Bank to indicate the status of the milk supply. Infants who 
are the main recipients of the donated pasteurised milk are 320 to 366 week (i.e. moderate to 













Age >5 days on PN
28-296/40
Age >5 days on PN/fluids
30-346/40
HIGH risk for NEC
Consider from birth (after maternal colostrum)
30-346/40
Low risk
Consider from birth (after maternal colostrum)























4.2.2 Phase One ethics  
The milk analysed as part of this study had already been donated to the Human Milk Bank. 
The donor mothers were contacted by the Human Milk Bank Manager who informed them of 
the study. They were given an information sheet (Appendix F) so that they were aware of the 
detail of the research and were informed that if they did not want their milk to be a part of the 
study, they had the option of not having it included. Because they were not being asked to do 
anything in addition to a usual Human Milk Bank donation, and identifiable data was not 
being collected, the donors were not asked to provide written consent. Ethical approval for the 
study was obtained from the Human Ethics Committee of the University of Otago, Dunedin, 
New Zealand (reference number H18/076 Appendix G). 
Minimal Supply 
Plentiful Supply 
(Adapted from current prioritisation tool authorised by Canterbury District Health 
Board human milk executive) 





4.2.3 Phase One samples 
This observational milk analysis study was conducted using all the human milk samples 
collected by the Human Milk Bank within the NICU at Christchurch Women’s Hospital from 
July 2018 to September 2018. There were no current donors who objected to having their 
milk included as part of this study. All research personnel, except the Human Milk Bank 
Manager, were blinded throughout data collection to the donors’ identification details, 
including characteristics associated with each sample (gestational age, and sex, of the infant; 
lactation stage of the donated milk (colostrum, preterm or term); and infant age when the 
sample was expressed). A range of milk lactation stages were analysed because the Human 
Milk Bank collects colostrum, preterm and term milks so the analysis of all three types of 
milk was necessary to describe the Human Milk Bank milk supply fully. Information was 
collected, and records stored by the Human Milk Bank Manager. 
4.2.4 Preparation of milk samples 
While the processes described in Section 4.2.1 ‘Human Milk Bank processes’ were being 
followed, approximately 20ml of each batch of donor sample of breast milk was decanted into 
two types of small containers (130ml and 30ml volume) by the Human Milk Bank Assistant 
after the pooled sample had been mixed. The two sized containers reflected whether the milk 
sample was being pasteurised or not – with the 130ml container being the correct size for the 
pasteuriser and the 30ml container appropriately sized for the Ultrasonic Processer (Miris AB, 
Uppsala, Sweden) for homogenisation. The milk in the 130ml container was pasteurised, the 
other was set aside for analysis as an unpasteurised sample. Samples were transferred to a 
refrigerator and held at less than 4°C for 4-72 hours after Holder pasteurisation prior to 
analysis.  
4.2.5 Human Milk Analyser protocol 
The nutritional composition of the milk was measured using the MIRIS Human Milk 
Analyser (HMA) (Miris AB, Uppsala, Sweden). This uses mid-infrared transmission 




analyser were total fat, crude or total protein, true protein, total carbohydrate (all in g/100ml), 
whereas total solids (g/100ml) and energy content (kcal/100ml) were calculated (155). Total 
carbohydrate includes lactose and oligosaccharide concentrations and crude protein includes 
protein and non-protein nitrogen content. True protein corrects for this so represents actual 
protein in samples. Miris uses a conversion factor of 6.38 to convert nitrogen content to 
protein (155). The HMA has an appointed measuring range for the macronutrients as follows: 
fat (0.6 – 5.9g/100ml), crude protein (0.8 – 3g/100ml), true protein (0.6 – 2.4g/100ml), 
carbohydrate (4 – 8g/100ml) (155). This range for each macronutrient, calculated by Miris, 
was decided by the concentration range of macronutrients in the calibration samples based on 
the normal variance found in human milk, ensuring the HMA could cover the spectrum of 
concentrations levels found in human milk. The number of samples whose nutrient 
components were measured to be outside of these ranges were noted by the Candidate. A 
recommended detailed Miris protocol was followed at all times. This protocol of the HMA set 
up and analysis (including a photo of the HMA labelled with its main components) is 
described in Appendix H.  
4.2.5.1 Human milk analysis 
Calibration of the HMA was conducted each day (Appendix H). The Miris recommended 
check and clean of the HMA was performed by the Candidate every 10th analysis as per the 
manufacturer’s instructions (155) (Appendix H).  
The milk analysis was carried out as follows: the pre and post pasteurisation samples 
of milk collected for analysis were placed into a water bath to heat them to 40°C. This was 
staggered so that the individual milk samples did not have prolonged exposure to heat. Once 
they had reached 40°C the samples were gently inverted approximately 10 times to ensure 
mixing of the milk. All samples were measured by syringe and transferred into a new 
container. The majority of the samples were 20ml and were homogenised with the ultrasonic 
processor (Miris AB, Uppsala, Sweden) for 30 seconds (1.5sec/ml) immediately prior to 




homogenisation time was adjusted accordingly. A 3ml sample was injected into the HMA via 
syringe and analysis was performed. There were 3 x 3ml (9ml overall) samples analysed per 
20ml sample of breast milk. The use of these triplicates is described in the statistical analysis 
section (4.2.6). For an illustration demonstrating the milk sample selection process and 
overall sample numbers, please refer to Appendix I. The milk samples were placed back into 
the water bath between analyses to ensure that a temperature of 40°C was maintained. Gentle 
inversion of the milk between analyses was done to ensure the milk was fully mixed in order 
to avoid separation.  
4.2.6 Phase One Statistical Analysis 
As much data was collected as possible within a two-month timeframe, aiming for a sample 
size of 50 to achieve reliable estimates of association with pasteurisation and maternal 
characteristics (182). The characteristics of the donors and the donors’ breast milk samples 
were normally distributed so are expressed as mean and standard deviation (SD), or number 
and percentage. To compare the energy and nutrient concentrations of pre and post 
pasteurisation samples of donor breast milk, mixed effects regression models were used with 
sample number nested in donor ID as random effects. This meant that both the multiple 
samples from the same donor and the triplicate values were accounted for. Mean difference, 
95% confidence intervals and p-values were calculated for differences between pasteurised 
and unpasteurised donor milk.  The energy and macronutrient variation for pre- and post-
pasteurisation samples of breast milk composition are depicted as box and whisker plots. 
Lactation stage and ‘lactation stage determined by sex’ column graphs used post 
pasteurisation samples of breast milk and at least ten “bin ranges” were provided for each 
nutrient, as this was considered likely to show a normal distribution if one was present.  
To measure the impact of three key maternal characteristics on the composition of 
donor breast milk: the gestational age of the donor’s infant at birth (in weeks), sex of the 
donor’s infant, and number of weeks between the infant’s birth and collection of the breast 




used with the post-pasteurisation nutrient composition. A separate regression analysis was 
performed for energy and each macronutrient (fat, protein, carbohydrate). Random effects for 
sample number nested in donor ID were included and both unadjusted and adjusted (for the 
other maternal characteristics) models were undertaken. This meant that both the multiple 
samples from the same donor and the triplicate values were accounted for. Regression 
coefficients (B), 95% confidence intervals and p-values were generated for each regression 
analysis. Five batch samples (or 15 samples in triplicate measures) were excluded from the 
regression analysis, three as the donor of the milk samples was a mother of twins, and two 
because they were colostrum samples. As term milk and a combination of gestational age and 
lactation stage were different ways of measuring the same concept, these three variables were 
not included in a model together. Models were also investigated with a number of interaction 
terms to assess multiplicative relationships between predictors. This indicated that 
interactions between gestational age and lactation stage are very likely, and that the 
relationship between lactation stage and milk composition is likely to be non-linear. The 
Candidate remained blinded to individual donors’ characteristics throughout the statistical 
analysis.  
4.3 Phase Two – Retrospective Nutrition and Growth Audit 
4.3.1 Study Design and participants 
The Christchurch Neonatal Intensive Care Unit (NICU) has 42 beds, three levels of care and 
admits a mean of 900 infants per year (both preterm and term infants), approximately 280 
(31%) of these admissions being moderate to late gestation (i.e. 320 to 366 weeks). This 
retrospective comparative audit collected data on 142 infants admitted to the Neonatal 
Intensive Care Unit (NICU) of Christchurch Women’s Hospital between 1 January 2013 and 
31 December 2013, and between 1 January 2016 and 31 December 2017.  This was a 
comparison audit comparing infants born in 2013 born prior to the establishment of the 




was established and who were recipients of pasteurised donated breast milk provided by the 
Human Milk Bank.  
Singleton and twin 320 to 366 weeks’ gestation infants were included in the study. 
Infants were excluded if they had congenital malformations requiring surgery, were born 
outside of Christchurch, were inpatients of maternity wards prior to or after being inpatients 
in NICU, died before hospital discharge, were diagnosed with necrotising enterocolitis, had 
missing nutrition data from their clinical notes, were the second twin of a twin set, were a 
triplet, or were transferred between hospitals with a stay in Christchurch Women’s Hospital 
NICU of 6 days or less. A single exception was made to these exclusion criteria – both twins 
of one twin set was were included in the 2016/17 cohort, as there would have been not enough 
infants to complete a full match to the 2013 cohort. Infants in the 2013 cohort were randomly 
selected, and infants in the 2016/17 cohort were matched by gestational age, sex and twin 
status to a 2013 infant, with eligible infants from throughout the time period (January 2016 to 
December 2017) having equal opportunity to be matched. 
Preterm infants with a gestational age between 320 and 366 weeks who were an 
inpatient of Christchurch NICU were identified using the ANZ Neonatal Network database 
which contains information on preterm births throughout Australasia. The selection process is 
described in Figure 4.2. In total, 282 eligible infants were identified from the year 2013. A 
random selection of these infants was identified by selecting every 5th infant born that year. 
This provided 57 infants for 2013. To achieve an adequate sample size, a further random 
selection of infants from the 2013 cohort was carried out by selecting every 7th infant for that 
year, providing a further 32 infants. This gave a total number of infants for the 2013 cohort of 
71. During data collection, 18 infants were excluded for reasons listed in the exclusion criteria 
above. The ‘missing data’ exclusion criterion was not applied to infants who had missing 
length measurements.  
To identify infants from 2016/17 to match with those from 2013, only infants who 




infants in the 2013 cohort for gestational age, sex and twin status. The reasons for solely 
including infants who were recipients of donor milk were that it aligned with the study 
objectives and the comparative nature with the 2013 cohort. If this was a larger study, all 
infants from 2016 (recipients of donor milk or not) would be included. In the 2016 cohort, 
there were 150 eligible infants who had received pasteurised donor milk (out of a total of 282 
preterm infants 320 to 366 weeks). The matching was done in a randomised fashion by 
ordering all eligible infants by gestational age, sex and twin status, then identifying infants 
depending on the required number to match to 2013. Sampling into 2017 data was required to 
enable a complete match to 2013 infants and lessen the chance of both twins from twin sets 
being included. This however was not entirely possible, with the inclusion of one twin set as 
not all eligible 2013 infants could be matched otherwise. In the 2017 cohort, there were 215 
eligible infants who had received pasteurised donor milk (out of a total of 279 preterm infants 
320 to 366 weeks), seven of whom were chosen to match with the 2013 cohort. They were 
chosen as the first born of their gestational age and sex for that year. During data collection, a 
further 13 infants were excluded for reasons listed in the exclusion criteria. Further infant 
selection used additional eligible infants from the 2016 cohort, and if required, eligible infants 
from the 2017 cohort. The final total number of infants was 57 from 2016 and 14 from 2017, 
the total combined sample being 71 infants for 2016/17. 
4.3.2 Phase Two ethics  
Because this was a retrospective audit of hospital records designed to improve clinical 
practice in the hospital, and the identity of the patients whose data was audited was not 
disclosed, it was not necessary to gain ethical approval to conduct the study. Instead, an 
application (Appendix J) to carry out the audit was made to Christchurch Women’s Hospital, 
through the Women’s and Children’s Clinical Audit Committee. The application was 
approved allowing the Candidate and her clinical supervisors to have research permission to 


































Figure 4.2: Illustration of the retrospective audit sample selection process of preterm infants (320 to 366 weeks’ gestation) 
from 2013 and 2016/17 cohorts 




4.3.3 Phase Two data collection  
A sample size of at least 50 infants per cohort was aimed for, in order to achieve reliable 
estimates of association (182).  The data collected for each infant were under three sections: 
demographic characteristics, growth measurements, and nutrition interventions and outcomes  
(see Table 4.1 below). 
 
Table 4.1: Type of data collected for each infant for 2013 and 2016/17 cohorts of 
moderate to late preterm infants 
Demographic 
characteristics 
Growth Measurements Nutrition interventions and outcomes 
Measure How this was 
recorded 
Measure How this was 
recorded 
Measure How this was 
recorded 
Gestational 
age at birth 





in grams (g) 
 
Hours from birth 
till first enteral 
feed 












Type of first 
enteral feed 
Expressed breast milk, 
pasteurised donor 
























for age, length 










age at birth 
Days to reach 
150ml/kg (i.e. 
full enteral feeds) 
Approximate number 









days to regain 
birth weight 
If weight loss 







given to infant 
Human milk fortifier 
(HMF),  
























pasteurised donor milk 










Growth Measurements Nutrition interventions and outcomes 
Measure How this was 
recorded 
Measure How this was 
recorded 



















Parenteral (starter or 
standard bag, lipid) 
















Number of days 
administered 
Approximate number 
of days administered 
  Discharge z-
scores: weight 
for age, length 




















reference ranges of 
each parameter 
    Daily nutrition 
intake for stay as 
NICU inpatient  
Quantities and type of 
all nutrition recorded: 
enteral, intravenous, 
supplementation 
    Calculations of 
daily energy and 
macronutrients 







reference values  
    Discharge 
nutrition  
Breast milk only, term 
infant formula only, 
premature infant 
formula only, 
combinations of breast 
milk and formula, 
additional 
supplementation 
    Discharge 
method of 
feeding  
Breast only, bottle 
only, breast and bottle 
combinations, 
Nasogastric tube 
Abbreviations: NICU – Neonatal Intensive Care Unit, HMF – Human Milk Fortifier 
 
 
Data were collected for each infant using hospital clinical notes and Health Connect South – 
an online patient viewing platform which is a portal from multiple databases. Data which 
were not recorded were entered as ‘not taken’. The majority of data were available in the 
clinical notes, which were supplemented with some biochemistry data (plus the respective 





Cormack et al.’s (39) work on standardised reporting of neonatal data (the StRoNNG 
checklist) was used for reference parenteral nutrition values when calculating energy from 
macronutrients, units of measurements for macronutrient calculations, the reporting of z-
scores, and the definition of full enteral feeds (i.e. reaching 150ml/kg/day). The definition of 
exclusive breastfeeding from the World Health Organization (WHO) was used: “the infant 
receives breast milk (including expressed breast milk, donor milk, or breast milk from a wet 
nurse) and allows infants to receive oral rehydration solutions, drops, syrups (vitamins, 
minerals, medicines), but nothing else” (183). This definition allows additives such as human 
milk fortifier (HMF) and singular macronutrient supplements (i.e. Duocal, Protifar, Calogen, 
Polycal) (183). This definition was chosen rather than the one from the New Zealand Ministry 
of Health because the ‘Neo-BFHI’ guidelines (which uses the WHO definition) (183) are used 
in the Human Milk Bank in Christchurch.  
4.3.3.1 Growth z-scores 
Z-scores for weight-for-age, length-for-age and head circumference-for-age at birth and 
discharge were calculated using an online calculator for preterm infants: ‘PediTools’ (184), 
which is based on the Fenton 2013 growth charts. This calculator calculates z-scores by using 
the following information: sex, gestational age, weight, length, head circumference, birth date 
and analysis date. Currently, the Christchurch NICU use UK-WHO growth charts, so it could 
result in discrepancy between recorded figures on growth charts and calculated z-scores for 
this study. The Lambda Mu Sigma method as stated in the StRoNNG checklist (39) was not 
used as it was deemed too complex for this small study.  
4.3.3.2 Macronutrient calculations 
Daily macronutrient intake (fat, protein, carbohydrate) and energy for each infant was 
manually calculated by the Candidate using information from the daily progress charts. This 
was done using standardised reference methods for the nutritional composition of parenteral 
nutrition, lipid, dextrose, term infant formula, premature infant formula, human milk fortifier 




If an infant received expressed breast milk or was breastfed, the reference values used 
were from Boyce et al. (97) which outlines preterm milk composition for week 1 – 8 of milk 
production. The Boyce et al. carbohydrate reference value with the majority of citations was 
chosen. If an infant consumed milk at the breast, the volume consumed was estimated by the 
breastfeeding code indicated on the progress chart, as well as the actual prescribed volume of 
fluid for that day. If an infant received pasteurised donated breast milk, reference values from 
Gildewitz et al (9) (as referred to in the HMA user manual (185)) were used. It is important to 
note that these figures are based on non-pasteurised mature term breast milk. The figures for 
mature term milk provided by Gildewitz et al. (9) were also used for one infant once their stay 
as a NICU inpatient surpassed 56 days (8 weeks). There was one infant who consumed 
‘Bellamy’s Organic Infant Formula’ while in NICU, the composition of which was found 
online (186) and used for the macronutrient and energy calculations. References values for all 
components are listed in Table 4.2 – 4.4. Ideally the results from the Phase One analysis of 
milk would have been used to conduct these Phase Two analyses of nutrient intake. However, 
due to the time constraints of an MDiet thesis, the two phases had to be carried out in parallel. 
Calculations for daily intake were carried out using the following formula:   
Reference value (g/ml) x ml/day = g/day or kcal/day 
g/day + g/day ……. = total g/day or kcal/day 
Total g/day / (weight (kg)) = g/kg/day or kcal/kg/day 
 
Grams per day (g/day) were calculated for all feeds an infant received, plus all additives they 
had, and this was then divided by the infant’s most recent weight. All macronutrients were 
reported in g/kg/day and energy in kcal/kg/day as per the StRoNNG checklist (39). Prior to 
analysis, the daily nutrient and energy intake for each infant was condensed into two variables 
– a median intake for week one as an inpatient of NICU and a median intake for week two 
until discharge. The number of days being an inpatient in NICU was noted for both variables 





1 Reference: Boyce et al. (97) 
2 Reference: Gidrewitz et al. (9), as seen in Miris HMA user manual (155) 
3 Reference: Wyeth S-26 Gold LBW (187) 
4 Reference: Nestle PreNAN Gold (187) 
5 Reference: Wyeth S-26 Original Newborn (188) 
6 Reference: Nutricia Karicare Plus Infant 1 (187) 
7 Reference: Bellamy’s Organic (186) 
 
*In per 1ml not 100ml  
-  Indicates minimal or no trace of macronutrient 
1 Reference: Cormack et al. (39) 
2 Reference: Solution produced by ‘Baxter’ specifically for Christchurch Neonatal Intensive Care Unit.  
[Starter 300ml bag: Protein 9g, Glucose 30g; Standard 650ml bag: Protein 19g, Glucose 65g] 
3 Reference: Solution produced by ‘Baxter’ specifically for Christchurch Neonatal Intensive Care Unit. 
[Starter 300ml bag: Protein 10.5g, Glucose 30g; Standard 650ml bag: Protein 22.8g, Glucose 65g] 
4 Reference: SMOFlipid (189)  
5 Reference: Solution produced by ‘Baxter’ specifically for Christchurch Neonatal Intensive Care Unit. 
[10% dextrose: Glucose 10g; 12.5% dextrose: Glucose 10g x 1.25; 15% dextrose: Glucose 10g x 1.5] 
 
 
Table 4.2: Reference values for macronutrient and energy calculations for breast milk and 
infant formulas 
 g/100ml kcal/100ml 
Reference source Protein Fat Carbohydrate Energy 
Expressed breast milk1     
Week 1 1.9 2.59 5.66 57.11 
Week 2-8 1.27 3.46 6.15 65.6 
Pasteurised donor breast milk2 1.0 3.4 6.5 63 
Premature infant formula     
20133 2.2 4.4 8.4 82 
2016/174 2.9 4.0 8.1 80 
Term infant formula      
Born February till July5 1.5 3.6 7.2 67.2 
Born August till January6 1.4 3.3 7.6 66. 
Organic Formula7  1.7 3.7 7.2 68.59 
Table 4.3: Reference values for macronutrient and energy calculations for parenteral 
nutrition, and intravenous dextrose  
 g/100ml kcal/ml* 
Reference source Protein Fat Carbohydrate Energy1 
    Protein Fat Carbohydrate 
Parenteral Nutrition  
(for 2013)2 
      
Starter 3.0 - 10 4 - 3.4 
Standard 2.9 - 10 4 - 3.4 
Parenteral Nutrition  
(for 2016/17)3 
      
Starter 3.5 - 10 4 - 3.4 
Standard 3.5 - 10 4 - 3.4 
Lipid4 - 20 - - 10 - 
Dextrose5       
10% - - 10 - - 3.4 
12.5% - - 12.5 - - 3.4 




*In per 1ml not 100ml  
- Indicates minimal or no trace of macronutrient 
1 Reference: Nutricia (187) 
2 Reference: Nutricia: Advanced Medical Nutrition (190) 
3 Reference: Nutricia: Advanced Medical Nutrition (191) 
4 Reference: SHS Nutricia (187) 
5 Reference: Nutricia: Advanced Medical Nutrition (192) 
 
4.3.4 Phase Two Statistical Analysis  
As much data were collected as possible within a two – month timeframe, aiming for a 
sample size of 50 per cohort to achieve reliable estimates of association (182). The 
characteristics of the infants were normally distributed so are expressed as mean and standard 
deviation (SD) or number and percentage. A matched analysis was performed with infant 
pairs from the 2013 and 2016/17 cohorts matched by gestational age, sex and twin status. 
Singleton and twin infants were both analysed together, with the presence of twins accounted 
for during analysis. Paired t-tests were used to determine mean differences between cohorts. 
For the calculated median energy and nutrient intake of infants, the mean of the median was 
taken for two variables, the first being week one of being an inpatient of NICU and second, 
week two until discharge from NICU.  
4.4 Statistical Analysis  
Data were collected and input into Microsoft Excel where analysis of number and 
percentages, some means and standard deviations, medians and quartile calculations and the 
generation of all graphs – column and box and whisker – was undertaken. Stata 15.1 
(StataCorp, Texas) was used for statistical tests and models. A p <0.05 was considered to 
indicate statistical significance.   
Table 4.4: Reference values for macronutrient and energy calculations for additives 
(human milk fortifier, macronutrient supplements)  
 g/100ml kcal/100ml 
Reference source Protein Fat Carbohydrate Energy 
Human milk fortifier1     
1 sachet 0.6 - 1.4 8 
2 sachets 1.2 - 2.8 16 
Protifar2     
0.5g 0.445 0.01 0.0075 1.9 
1g 0.89 0.02 0.015 3.8 
Polycal, 1g3  - - 0.96 3.8 
Duocal, 1g4 - 0.22 0.73 5 
 g/ml* kcal/ml* 






5.1 Phase One – Donor Breast Milk Analysis 
A total of 378 analyses were performed with the Human Milk Analyser (HMA). This 
comprised 126 samples of batch donor milk (i.e. pre- and post-pasteurisation samples for 63 
donated samples), each analysed in triplicate. The 63 batch samples of donated breast milk 
were from 27 donor mothers. Table 5.1 summarises key characteristics of both the milk 
samples and the donors who provided the samples. Of the 63 samples, 50 samples were term 
breast milk (79%), 11 were preterm (18%), and two were colostrum (3%). The mean 
gestational age of the donor’s infant was 34 weeks (± 5.2 weeks) at birth, although mothers of 
preterm infants provided both preterm and term milk, depending on whether the milk was 
provided when their infant was younger or older than 37 weeks corrected gestational age. The 
number of donors with male and female infants was the same.  
Table 5.1: Key characteristics of donors and donated breast milk samples from the Human 
Milk Bank at Christchurch Women’s Hospital Neonatal Intensive Care Unit  
Characteristic n (%) 
Total number of samples donated1, n 63 
Total number of pre and post pasteurisation samples1, n 126 
Number of donor women, n 27 
Number of samples from same donor  
One sample 12 (44%) 
Two to three samples 10 (37%) 
Four to eight samples 5 (19%) 
Sex of donor’s infant2, n  
Male 14  
Female 14  
Gestation of donor infant at birth, weeks, mean (SD) 34 (5.2) 
Lactation stage of breast milk sample  
Colostrum3 2 (3%) 
Preterm 11 (18%) 
Term 50 (79%) 
Days from birth until milk donation by lactation stage, mean (SD)  
Colostrum 2 days (0.0) 
Preterm 17 days (7.8) 
Term 105 days (69.6) 
Source of breast milk sample  
Community  25 (40%) 
Neonatal Intensive Care Unit  38 (60%) 
Data presented as n (%) unless stated otherwise 
163 samples were donated, each of which was analysed pre and post pasteurisation (i.e. n=126) with each of 
these samples being analysed in triplicate (i.e. n=378 analyses). See section 4.2.6 for an explanation of how 
these triplicates were included in the models. 
2 Set of male and female twins from one donor (infants n =28) 




5.1.1 Effect of pasteurisation on donor milk and sample composition variance 
Table 5.2 indicates Holder pasteurisation had a significant effect on the energy, fat and total 
carbohydrate (all p≤0.001) of donor breast milk, with all measures slightly lower after 
pasteurisation (change ≤3%). Protein concentration was not significantly affected by the 
pasteurisation process.  
Bold indicates a statistically significant difference of p <0.05 
1Each of the 63 batch samples provided a pre- and a post-pasteurisation value (i.e. n=126). Each of these 126 
samples was analysed in triplicate – see section 4.2.6 for an explanation of how these triplicates were included in 
the models. Samples of colostrum, preterm and term milk are included in the analysis and multiple samples from 
the same donor taken into account. 
2Protein here represents true protein, which is bioavailable Nitrogen (total nitrogen – non protein nitrogen) x 
6.38 (conversion factor) (97, 193). True protein is corrected for so this better represents the concentration of 
actual protein (155) – (Crude protein results can be found in Appendix K) 
 
 
Figures 5.1a – 5.1d show the variability in energy content and macronutrient concentrations 
in samples of donor breast milk. Post-pasteurisation energy concentration ranged from 49 to 
90 kcal/100ml of breast milk, fat from 1.4 to 5.7g/100ml, protein from 0.5 to 1.6g/100ml, and 
total carbohydrate concentration from 7.3 to 8.5g/100ml. The variability in the pre-
pasteurisation samples was very similar for these nutrient and energy concentrations. The 
presence of a number of outliers on the graphs, particularly for protein (Figure 5.1c), suggests 





















Energy (kcal/100ml) 69 (10) 68 (9) -1.0 (-1.4, -0.5) <0.001 
Energy (kJ/100ml) 289 (42) 285 (38) -4.2 (-5.9, -2.1) <0.001 
Fat (g/100ml) 3.5 (1.0) 3.4 (1.0) -0.10 (-0.15, -0.06) <0.001 
Protein2 (g/100ml) 0.9 (0.2) 0.9 (0.2) 0.005 (-0.001, 0.012) 0.123 




Figure 5.1 a – d: Variation per 100ml of donor breast milk for pre and post pasteurisation samples (n=63 
batch samples each providing a pre- and post- pasteurisation value). This includes colostrum, preterm and 
term samples.  
Dots indicate outliers which are larger than the 3rd quartile by 1.5 x interquartile range (IQR) or smaller than 





















































Figure 5.1a: Variation in energy content  
 
 



































1Protein here represents true protein, which is bioavailable Nitrogen (total nitrogen – non-protein nitrogen) x 
6.38 (conversion factor) (97, 193). True protein is corrected for so it better represents the concentration of actual 































Figure 5.1c: Variation in protein1 
concentration  
 




























Energy content of pasteurised donor breast milk (kcal/100ml)
Colostrum Preterm Milk Term Milk
There were 24 post-pasteurisation samples for which total carbohydrate concentrations 
measured above the HMA reference constraint of 8.0g/100ml, and one sample for which 
protein measured below the HMA reference constraint of 0.6/100ml (155). The total number 
of samples measuring outside the HMA reference range was slightly higher for pre-
pasteurisation samples (total of 32 including two fat measures above 5.9g/100ml). 
5.1.2 Compositional variation of donor breast milk by lactation stage 
Figures 5.2a – d show the distribution of energy and each macronutrient as colostrum, 
preterm and term pasteurised donor breast milk samples. Visual inspection suggests the 
distribution of term milk samples was normal. The bins which were most highly represented 
for term milk were 65 – 69kcal energy, 3.0 – 3.4g fat, 0.7g protein, and 7.9g total 
carbohydrate per 100ml of breast milk.  Interestingly, variation in macronutrient and energy 
content was slightly different depending on whether the donor mother had a male or female 















Figure 5.2a: Categorising energy content of colostrum, preterm and term pasteurised 


























Fat concentration of pasteurised donor breast milk (g/100ml)























Protein concentration of pasteurised donor breast milk (g/100ml)



























Figure 5.2c: Categorising protein1 concentration of colostrum, preterm and term pasteurised 
donor breast milk (g/100ml) 
 
1Protein here represents true protein, which is bioavailable Nitrogen (total nitrogen – non-protein nitrogen) x 
6.38 (conversion factor) (97, 193). True protein is corrected for so it better represents the concentration of actual 
protein (155) – (Crude protein results can be found in Appendix K) 
Figure 5.2b: Categorising fat concentration of colostrum, preterm and term pasteurised 
























Total carbohydrate concentration of pasteurised donor breast milk (g/100ml)


















5.1.3 Multiple regression analysis of maternal characteristic impact on 
composition 
 
The three maternal characteristics tested (lactation weeks of the donor including term 
compared to preterm milk, gestational age and sex of donor’s infant), did not appear to have 









Figure 5.2d: Categorising total carbohydrate concentration of colostrum, preterm and 




1Of the original 27 donors, one was excluded because she was a mother of twins (i.e. n=26). The final 
number of post pasteurisation samples used in the analysis was 58 following exclusion from the original 63 
samples of the 3 samples from the mother of twins, and the 2 colostrum samples. Each of these 58 samples 
was analysed in triplicate – see section 4.2.6 for an explanation of how these triplicates were included in 
the models. Multiple samples from the same donor were taken into account. 
2 Sex is adjusted for term milk and vice versa; gestational age and lactation stage are mutually adjusted for 
each other along with sex (i.e. term milk is not included in the same model as gestational age and lactation 
stage) 
3Coefficient shows change in kcal/100ml for each single unit change in the maternal characteristic – 





1Of the original 27 donors, one was excluded because she was a mother of twins (i.e. n=26). The final 
number of post pasteurisation samples used in the analysis was 58 following exclusion from the original 63 
samples of the 3 samples from the mother of twins, and the 2 colostrum samples. Each of these 58 samples 
was analysed in triplicate  – see section 4.2.6 for an explanation of how these triplicates were included in 
the models. Multiple samples from the same donor were taken into account. 
2 Sex is adjusted for term milk and vice versa; gestational age and lactation stage are mutually adjusted for 
each other along with sex (i.e. term milk is not included in the same model as gestational age and lactation 
stage) 
3Coefficient shows change in g/100ml for each single unit change in the maternal characteristic – negative 
values indicate a decrease in fat content, positive values indicate an increase. 
 
 
The gestational age of the donor’s infant significantly affected the concentration of protein 
(Table 5.5), where for every week older in gestational age, protein was 0.01g/100ml lower. 
Table 5.3: Multiple regression analysis of the impact of maternal characteristics on the 
energy content of post pasteurisation donor breast milk1 
Maternal Characteristic Change in energy content (kcal/100ml) for each unit change in 
characteristic 
 Unadjusted Adjusted2 
 B3 (95% CI) p B3 (95% CI) p 
Sex of donor’s infant (boys 
compared to girls) 
-3.1 (-9.9, 3.7) 0.374 -3.1 (-9.7, 3.5) 0.358 
Gestational age of donor’s 
infant, weeks 
0.0 (-0.7, 0.6) 0.947 -0.1 (-0.8, 0.7) 0.873 
Lactation weeks of the 
donor, weeks 
0.0 (-0.3, 0.3) 0.931 -0.1 (-0.4, 0.3) 0.746 
Term milk, compared to 
preterm 
-3.8 (-10.1, 2.6) 0.246 -3.8 (-10.1, 2.5) 0.235 
Table 5.4: Multiple regression analysis of the impact of maternal characteristics on the 
fat concentration of post pasteurisation donor breast milk1 
Maternal Characteristic Change in fat concentration (g/100ml) for each unit change in 
characteristic 
 Unadjusted Adjusted2 
 B3 (95% CI) p B3 (95% CI) p 
Sex of donor’s infant (boys 
compared to girls) 
-0.36 (-1.05, 0.33) 0.311 -0.36 (-1.04, 0.32) 0.302 
Gestational age of donor’s 
infant, weeks 
0.01 (-0.06, 0.08) 0.765 0.00 (-0.08, 0.08) 0.993 
Lactation weeks of the 
donor, weeks 
0.01 (-0.02, 0.03) 0.721 0.00 (-0.04, 0.03) 0.967 
Term milk, compared to 
preterm 




This is for the unadjusted analysis but was no longer statistically significant in the adjusted 
model. Gestational age also significantly affected total carbohydrate concentration (Table 
5.6), where there was a 0.02g/100ml reduction in carbohydrate concentration with increased 
gestational age, after adjustment for other maternal characteristics.  
The lactation weeks of the donor significantly affected the concentration of protein in 
breast milk (p< 0.001; Table 5.5), with a 0.01g/100ml reduction in protein with increased 
lactation weeks. There was also a statistically significant difference (p≤0.001) for both 
unadjusted and adjusted term compared to preterm milk, where there was a 0.2g/100ml 
reduction in protein content if donor milk was from a mother whose infant was term age.  
 
 
Table 5.5: Multiple regression analysis of the impact of maternal characteristics on the 
protein1 concentration of post pasteurisation donor breast milk2 
Maternal Characteristic Change in protein (g/100ml) for each unit change in characteristic 
 Unadjusted Adjusted3 
 B4 (95% CI) p B3 (95% CI) p 
Sex of donor’s infant (boys 
compared to girls) 
0.07 (-0.06, 0.20) 0.292 0.07 (-0.05, 0.18) 0.238 
Gestational age of donor’s 
infant, weeks 
-0.01 (-0.02, -0.0005) 0.042 0.00 (-0.01, 0.02) 0.686 
Lactation weeks of the 
donor, weeks 
-0.01 (-0.02, -0.01) <0.001 -0.01 (-0.02, -0.01) <0.001 
Term milk, compared to 
preterm 
-0.19 (-0.30, -0.09) <0.001 -0.20 (-0.30, -0.09) <0.001 
Bold indicates a statistically significant difference of p <0.05 
1Protein here represents true protein, which is bioavailable Nitrogen (total nitrogen – non protein nitrogen) 
x 6.38 (conversion factor) (97, 193). True protein is corrected for so it better represents the concentration of 
actual protein (155) – (Crude protein results can be found in Appendix K) 
2Of the original 27 donors, one was excluded because she was a mother of twins (i.e. n=26). The final 
number of post pasteurisation samples used in the analysis was 58 following exclusion from the original 63 
samples of the 3 samples from the mother of twins, and the 2 colostrum samples. Each of these 58 samples 
was analysed in triplicate – see section 4.2.6 for an explanation of how these triplicates were included in 
the models. Multiple samples from the same donor were taken into account. 
3Sex is adjusted for term milk and vice versa; gestational age and lactation stage are mutually adjusted for 
each other along with sex (i.e. term milk is not included in the same model as gestational age and lactation 
stage) 
4Coefficient shows change in g/100ml for each single unit change in the maternal characteristic – negative 














Table 5.6: Multiple regression analysis of the impact of maternal characteristics on the 
total carbohydrate concentration of post pasteurisation donor breast milk1 
Maternal Characteristic Change in total carbohydrate concentration2 (g/100ml) for each 
unit change in characteristic 
 Unadjusted Adjusted3 
 B4 (95% CI) p B4 (95% CI) p 
Sex of donor’s infant (boys 
compared to girls) 
-0.04 (-0.22, 0.13) 0.630 -0.05 (-0.21, 0.12) 0.573 
Gestational age of donor’s 
infant, weeks 
-0.01 (-0.03, 0.002) 0.095 -0.02 (-0.04, -0.00) 0.050 
Lactation weeks of the 
donor, weeks 
0.00 (-0.01, 0.01) 0.719 0.00 (-0.01, 0.01) 0.588 
Term milk, compared to 
preterm 
-0.15 (-0.33, 0.03) 0.102 -0.15 (-0.33, 0.03) 0.095 
Bold indicates a statistically significant difference of p <0.05 
1Of the original 27 donors, one was excluded because she was a mother of twins (i.e. n=26). The final 
number of post pasteurisation samples used in the analysis was 58 following exclusion from the original 63 
samples of the 3 samples from the mother of twins, and the 2 colostrum samples. Each of these 58 samples 
was analysed in triplicate – see section 4.2.6 for an explanation of how these triplicates were included in 
the models. Multiple samples from the same donor were taken into account. 
2 Total carbohydrate concentration includes lactose and oligosaccharides 
3Sex is adjusted for term milk and vice versa; gestational age and lactation stage are mutually adjusted for 
each other along with sex (i.e. term milk is not included in the same model as gestational age and lactation 
stage) 
4Coefficient shows change in g/100ml for each single unit change in the maternal characteristic – negative 
values indicate a decrease in total carbohydrate content, positive values indicate an increase. 
 
5.2 Phase Two – Retrospective Nutrition and Growth Audit 
5.2.1 Characteristics of study sample 
A total of 142 infants met the inclusion criteria, while 231 moderate to late (320 to 366 weeks) 
preterm infants were excluded. Reasons for exclusion were as follows: did not receive 
pasteurised donated breast milk; maternity ward inpatient prior to or post NICU; in another 
hospital first before Christchurch Women’s; missing nutritional data; second twin of set; a 
triplet; or inpatient in NICU for 6 days or fewer before transfer to another hospital.  
Table 5.7 summarises the key characteristics of the total sample and matched samples 
for each cohort year (with separation of 2016 and 2017 in this table). For 2016, 53% of 
moderate to late preterm infants were recipients of donor breast milk, which increased to 77% 
in 2017. There was only one case of a documented diagnosis of necrotising enterocolitis in all 






Data presented as n (%) unless stated otherwise 
12013 infants were randomly selected from all Neonatal Intensive Care Unit infants who were moderate to 
late preterm (320 to 366 weeks). Infants from the 2016/17 cohort were randomly chosen from all Neonatal 
Intensive Care Unit infants who were moderate to late preterm (320 to 366 weeks) and were recipients of 
pasteurised donor breast milk, and matched an infant from 2013 in terms of gestational age, sex and twin 
status. 
2Characteristics from both years are presented separately to show total numbers from each year and 
matched cohort numbers. 2016 and 2017 data are otherwise combined 
 
 
Table 5.8: Comparison of the demographic characteristics of the study sample of moderate 
to late preterm (320 to 366 weeks) infants admitted as an inpatient to the Christchurch 
Neonatal Intensive Care Unit (n=71 matched pairs)  
 2013 2016/17   
 (n=71) (n=71) Mean Difference 
(95% CI) 
p 
Sex, n (%)     
Female  31 (44%) 31 (44%) - - 
Male  40 (56%) 40 (56%) - - 
Delivery mode, n (%)     
Vaginal birth  28 (39%) 28 (39%) - - 
Caesarean section  43 (61%) 43 (61%) - - 
Gestational age at birth 34.3 (1.3) 34.3 (1.3) 0 - 
Gestational age at Neonatal 
Intensive Care Unit 
discharge 
37.8 (1.3) 37.8 (1.3) 0 - 
Length of stay in Neonatal 
Intensive Care Unit, days 
24.2 (12.1) 25.2 (1.3) 1.0 (-2.0, 4.1) 0.510 
Data presented as mean (SD) unless stated otherwise 
- indicates no mean difference (95% CI) and/or p was calculated 
Table 5.7: Key characteristics of moderate to late (320 to 366 weeks) preterm infants 
admitted to the Christchurch Neonatal Intensive Care Unit in 2013, 2016 and 2017, and 
those matched for inclusion in this study1 
 2013 20162 20172 


















Sex       
Female 153 (54%) 31 (44%) 144 (51%) 28 (49%) 131 (47%) 3 (21%) 
Male 129 (46%) 40 (56%) 138 (49%) 29 (51%) 148 (53%) 11 (79%) 
Gestational Age       
32 weeks 26 (9%) 8 (11%) 38 (13%) 8 (14%) 31 (11%) 0 (0%) 
33 weeks 38 (14%) 13 (18%) 30 (11%) 11 (19%) 31 (11%) 2 (14%) 
34 weeks 81 (29%) 19 (27%) 61 (22%) 17 (30%) 63 (23%) 2 (14%) 
35 weeks 52 (18%) 15 (21%) 74 (26%) 11 (19%) 80 (29%) 4 (29%) 














As shown in Table 5.8, there were slightly more males than females represented in the 
matched pairs (40 to 31 infants respectively). Coincidently, the mode of delivery and 
gestational age at birth and discharge were exactly the same between the 2013 and 2016/17 
cohorts. 
 
5.2.2 Nutritional interventions and outcomes 
There was a significant increase (p<0.001) in the number of infants who were exclusively 
breast milk fed during their stay in the NICU, from 19 to 57 infants (27% to 72%) between 
the 2013 and 2016/17 cohorts (Table 5.9). All infants in the 2016/17 cohort had breast milk 
(expressed or donor) as their first enteral feed, as well as when reaching 120ml/kg/day enteral 
feeds. There was a reduction (although not reaching statistical significance) in the number of 
infant’s administrated intravenous dextrose (80% in 2013 to 69% in 2016/17) and parenteral 
nutrition (11% to 4% respectively) for donor milk recipients. 
Table 5.10 shows the nutritional outcomes for the two cohorts. There were no 
significant differences seen between cohorts for the mean concentration of low urea, albumin 
or sodium and there were similar infant numbers for plasma levels below the reference range 
per biochemistry measure. There were similar numbers of infants on breast milk only at 
discharge in the two cohorts, but there was a significant increase (p=0.014) in infant numbers 





Table 5.9: Comparison of nutrition interventions in the study sample of moderate to late preterm (320 to 366 weeks) infants admitted as an inpatient 
to the Christchurch Neonatal Intensive Care Unit (n=71 matched pairs)  
 2013 2016/17   





Type of first enteral feed, n (%)     
Expressed breast milk 69 (97%) 66 (93%) - - 
Pasteurised donor breast milk 0 5 (7%) - - 
Term infant formula 2 (3%) 0 - - 
Time of first enteral feed (hours from birth) 4.0 (0.9) 3.9 (0.9) -0.2 (-0.5, 0.1) 0.260 
Intravenous dextrose     
Number of infants administered IV dextrose, n (%) 57 (80%) 49 (69%) - 0.169 
Number of days administered for these infants1 2.6 (1.1) 2.1 (1.3) - - 
Parenteral nutrition      
Number of infants administrated parenteral nutrition, n (%) 8 (11%) 3 (4%) - 0.180 
Number of days administrated for these infants1 3.9 (2.0) 4.0 (0.0) - - 
Enteral nutrition2     
Number of days to reach 120ml/kg of enteral feeds 2.6 (0.9) 2.4 (0.8) -0.2 (-0.4, 0.1) 0.175 
Number of days to reach 150ml/kg of full enteral feeds 4.0 (0.9) 3.9 (0.9) -0.2 (-0.5, 0.1) 0.260 
Number of infants exclusively breast milk fed at 120ml/kg enteral feeds3, 4, n (%) 40 (56%) 71 (100%)   
Number of infants exclusively breast milk fed at 150ml/kg full enteral feeds3, 5, n (%) 32 (45%) 70 (99%)   
Number of infants exclusively breast milk fed throughout inpatient NICU3, n (%) 19 (27%) 51 (72%) - <0.001 
Macronutrient additives6     
Number of infants receiving additives overall, n (%) 15 (21%) 7 (10%) - - 
Number of infants receiving human milk fortifier, n  12  6  - - 
Number of infants receiving only other additives7, n 4 3 - - 
Data presented as mean (SD) unless stated otherwise 
Bold indicates a statistically significant difference of p <0.05 
- indicates no mean difference (95% CI) and/or p was calculated 
Abbreviations: IV – Intravenous  
1Figures displayed are for all infants receiving IV or parenteral nutrition. If looking at matched infant pairs then: IV dextrose – 3.0 (1.4) for 2013 and 2.4 (1.7) for 2016/17 
(n=40 matched) [mean difference -0.6 (-1.3, 0.1), p=0.106]. Parenteral nutrition – 3.0 for 2013 and 8.0 for 2016/17 (n=1 matched). 





3Exclusive breastfeeding is defined by the World Health Organization (WHO) as: the infant receives breast milk (including expressed breast milk, donor milk, or breast milk 
from a wet nurse) and allows infants to receive oral rehydration solutions, drops, syrups (vitamins, minerals, medicines), but nothing else (183). This also includes infants 
having additives such as human milk fortifier (HMF) and singular macronutrient supplements. 
4Counted as day 120ml/kg was reached. Type of feed: 2013 – [Expressed breast milk: 40 (56%); Infant formula: 3 (4%); Expressed breast milk + infant formula: 28 (40%)] 
  2016/17 – [Expressed breast milk: 4 (6%); Pasteurised donor milk: 1 (1%); Expressed breast milk + pasteurised donor milk: 66 (93%)] 
5Counted as day 150ml/kg was reached. Type of feed: 2013 – [Expressed breast milk: 32 (45%); Infant formula: 3 (4%); Expressed breast milk + infant formula: 36 (51%)] 
2016/17 – [Expressed breast milk: 18 (25%); pasteurised donor milk: 2 (3%); Expressed breast milk + pasteurised donor milk: 50 (71%); Expressed breast milk + 
pasteurised donor milk + infant formula: 1 (1%)] 
6Median day (min and max) fortification was started: 2013 – day 10 (5 – 25); 2016/17 – day 8 (5 – 18) 

































Table 5.10: Comparison of nutrition outcomes in the study sample of moderate to late preterm (320 to 366 weeks) infants admitted as an inpatient 
to the Christchurch Neonatal Intensive Care Unit (n=71 matched pairs) 









Plasma urea concentration1,2, mmol/L     
Lowest mean urea 2.9 (1.8) 2.5 (1.6) -0.4 (-1.2, 0.5) 0.405 
Number of infants with low urea as an inpatient in NICU3, n (%) 4 (6%) 4 (6%) - - 
Plasma albumin concentration2,4, g/L     
Lowest mean albumin (g/L) 30.0 (2.7) 27.2 (3.2) -2.8 (-4.2, -1.4) -  
Number of infants with low albumin as an inpatient in NICU3, n (%) 18 (25%) 21 (30%) - - 
Plasma sodium concentration2,5, mmol/L     
Lowest mean sodium (mmol/L) 138 (3) 137 (4) -1.0 (-2.0, 1.0) 0.369 
Number of infants with low sodium as an inpatient in NICU3, n (%) 10 (14%) 9 (13%) - - 
Discharge nutrition type, n (%)     
Expressed breast milk/breastfeeding only 55 (77%) 54 (76%) - - 
Term infant formula only 6 (9%) 6 (9%) - - 
Premature infant formula only 1 (1%) 0 - - 
Expressed breast milk/breastfeeding and term infant formula 4 (6%) 10 (14%) - - 
Expressed breast milk/breastfeeding and a macronutrient additive 










Discharge method of feeding, n (%)     
Breast only 15 (21%) 28 (40%) - 0.0146 
Bottle only7 15 (21%) 11 (15%) - - 
Breast and bottle7 17 (24%) 15 (21%) - - 
Breast with bottle top ups7 16 (22%) 17 (24%) - - 
Nasogastric tube 2 (3%) 0 - - 
Nasogastric tube and breast 4 (6%) 0 - - 
Nasogastric tube and bottle7 2 (3%) 0 - - 
Data presented as mean (SD) unless stated otherwise; - indicates no mean difference (95% CI) and/or p was calculated 
Bold indicates a statistically significant difference of p <0.05 
*P value for albumin was not calculated due to a change in the laboratory assay reference range between year groups. This could result in a false difference between groups. 
1Reference range urea: 1.1 – 6.1mmol/L (2013, 2016/17). Days of lowest measurements under reference range: median of day 5 and 29 (2013); day 16 and 38 (2016/17) 





3Only infants whose biochemistry measured below each corresponding reference range were counted 
4Reference range albumin: 30 – 45g/L (2013), 28 – 41g/L (2016/17) – the different reference ranges reflect the change in laboratory assay ranges between these two-year 
groups. Days of lowest measurements under reference range: median of day 3 (2013); day 2 and 23 (2016/17) 
5Reference range sodium: 135 – 145mmol/L (2013, 2016/17). Days of lowest measurements under reference range: median of day 3 (2013); day 2 and 28 (2016/17). 
6Direct comparison of proportions, ignoring matching. 






Table 5.11: Comparison of daily macronutrient and energy intake of moderate to late preterm (320 to 366 weeks) infants while in the Neonatal 
Intensive Care Unit (n= 71 matched pairs) 
 2013 (n=71) 2016/17 (n=71)   
 Mean (SD) Mean (SD) Mean Difference (95% CI) p 
Week one as inpatient of Neonatal Intensive Care Unit1     
Median Energy (kcal/kg/day) 66 (17) 71 (13) 4.9 (-0.02, 9.9) 0.051 
Median Fat (g/kg/day) 2.8 (1.2) 3.4 (0.9) 0.6 (0.3, 10.) <0.001 
Median Protein (g/kg/day) 1.7 (0.7) 1.5 (0.6) -0.2 (-0.4, -0.01) 0.036 
Median Carbohydrate (g/kg/day) 8.5 (1.2) 8.2 (1.2) -0.3 (-0.7, 0.1) 0.100 
Week two until discharge from Neonatal Intensive Care Unit1     
Median Energy (kcal/kg/day) 114 (12) 109 (16) -5.5 (-9.8, -1.1) 0.014 
Median Fat (g/kg/day) 5.9 (0.6) 5.7 (0.8) -0.2 (-0.4, -0.003) 0.047 
Median Protein (g/kg/day) 2.4 (0.5) 2.2 (0.5) -0.2 (-0.4, -0.1) 0.009 
Median Carbohydrate (g/kg/day) 11.1 (1.6) 10.5 (1.8) -0.7 (-1.2, -0.1) 0.013 
Bold indicates a statistically significant difference of p <0.05 
1Length of time as an inpatient of the Neonatal Intensive Care Unit has been separated into week one and week two until discharge to differentiate between early and later 




5.2.3 Median nutrient intake of moderate to late preterm infants 
The median nutrient intake for energy and macronutrients (fat, protein and carbohydrate) is 
summarised in Table 5.11. For week 1 of inpatient NICU stay, there were significant 
differences between cohorts, with increased daily energy (4.9kcal/kg) and fat (0.6g/kg) and 
lower protein (0.2g/kg) intakes for donor milk recipient infants in 2016/17 compared to 2013 
infants. For week 2 until discharge, there were significant differences between cohorts, with 
lower intakes for all macronutrients (mean difference for fat: 0.2g/kg; protein: 0.2g/kg; 
carbohydrate: 0.7g/kg) and energy (5.5kcal/kg) per day for donor milk recipient infants in 
2016/17 compared to 2013 infants.  
5.2.4 Growth differences between cohorts 
Table 5.12 describes the differences in growth measurements between infants before and after 
access to a human milk bank – at birth and at discharge. There were no statistically significant 
differences between the cohorts, but there was a small (although not statistically significant) 
improvement in discharge weight and length z scores for donor milk recipients (-1.01 vs -0.88 
and -0.47 vs -0.29 respectively). The z-scores on a whole remained negative suggesting that 
the infants’ growth was less than that of the population in general of the same age. There were 
infants in both cohorts with missing birth length measurements, however rates of missing data 









1Weight-for-age calculated using ‘PediTools’ online calculator based on Fenton 2013 growth charts (184) 
2Number of infants with missing length measurements, n (%): 2013 - 14 (20%), 2016/17 -6 (9%) 
3Length-for-age calculated using ‘PediTools’ online calculator based on Fenton 2013 growth charts (184) 
4Head circumference-for-age calculated using ‘PediTools’ online calculator based on Fenton 2013 growth charts (184) 
5Infants with no recorded weight loss after birth, n (%): 2013 - 5 (7%), 2016/17 - 6 (9%); Infants who did not regain birth weight before discharge, n (%): 2013- 5 (7%), 
2016/17 - 2 (3%) 
Table 5.12: Comparison of growth in the study sample of moderate to late preterm (320 to 366 weeks) infants admitted as an inpatient to the 
Christchurch Neonatal Intensive Care Unit (n=71 matched pairs) 
 2013 (n=71) 2016/17 (n=71)   
 Mean (SD) Mean (SD) Mean Difference (95% CI) p 
Birth weight, g 2162 (392) 2227 (532) 65 (-80, 210) 0.375 
Weight for age z score1 -0.45 (0.9) -0.37 (1.2) 0.08 (-0.27, 0.42) 0.652 
Birth length2, cm 44.7 (2.7) 45.5 (3.5) 0.8 (-0.4, 2.0) 0.185 
Length for age z score3 -0.23 (1.1) 0.05 (1.3) 0.27 (-0.20, 0.75) 0.520 
Birth head circumference, cm 31.3 (1.6) 31.4 (1.7) 0.1 (-0.4, 0.6) 0.727 
Head circumference for age z score4 -0.06 (0.94) -0.07 (1.20) -0.01 (-0.37, 0.35) 0.965 
Days to regain birth weight5 8.3 (4.4) 8.0 (4.0) -0.3 (-1.6, 1.0) 0.650 
Discharge weight, g 2650 (344) 2769 (462) 119 (-20, 258) 0.093 
Weight for age z score1 -1.01 (0.74) -0.88 (1.04) 0.13 (-0.16, 0.43) 0.371 
Discharge length, cm 47.8 (2.2) 48.5 (2.1) 0.7 (-0.02, 1.41) 0.057 
Length for age z score3  -0.47 (0.86) -0.29 (0.97) 0.17 (-0.15, 0.50) 0.285 
Discharge head circumference, cm 33.2 (1.3) 33.5 (1.2) 0.3 (-0.1, 0.6) 0.142 
Head circumference for age z score4 -0.37 (0.77) -0.29 (0.92) 0.07 (-0.19, 0.34) 0.571 
Change in z scores from birth to discharge     
Weight for age -0.6 (0.4) -0.5 (0.5) 0.07 (-0.04, 0.19) 0.219 
Length for age -0.4 (0.7) -0.3 (0.9) 0.15 (-0.09, 0.39) 0.218 




5.3 Comparison of phase one samples of donor breast milk and breast milk reference 
values used for phase two audit 
 
Table 5.13 shows differences between measured samples of preterm donor breast milk from 
phase one and the reference values used from phase two. There is a large difference between 
the energy content of measured samples and reference values, particularly for week one of 
preterm milk production. Samples measured in the Human Milk Bank with the analyser 
indicated expressed preterm milk had a calorie composition higher than the audit reference 
values. Fat concentration did not deviate too much, however the protein concentration was  
lower than reference values. Carbohydrate was much higher in measured samples, than the 
reference values, however these were lactose values only, with the analyser measuring total 
carbohydrate. If the known composition of oligosaccharides is added (from other reference 
values (9)), the difference is much smaller.  
Table 5.14 shows the differences between measured composition of term donor breast 
milk and the reference values used for the audit. Differences between each were much smaller 
than preterm milk, and once oligosaccharide content is taken into account for total 
carbohydrate, there are only small differences between the measured samples and reference 






















Table 5.13: Comparison of measured pasteurised donor breast milk samples and audit references values for preterm milk 




Mean (95% CI) 
 
Boyce et al. reference values used for 
Phase two (97) 
Week 1 Energy (kcal/100ml) 72 72 (47, 97) 57.11 
Week 2-8 75 (69 – 82) 75 (70, 81) 65.60 (63.27 – 67.17) 
Week 1 Fat (g/100ml) 3.4 3.4 (0.9, 6.0) 2.59 
Week 2-8 4.0 (3.5 – 4.6) 4.0 (3.4, 4.5) 3.46 (3.25 – 3.69) 
Week 1 Protein
3
 (g/100ml) 1.4 1.4 (1.1, 1.8) 1.90 
Week 2-8 1.1 (0.8 – 1.6) 1.1 (0.9, 1.3) 1.27 (1.02 –1.58) 
Week 1 Total Carbohydrate 
(g/100ml) 
8.0 8.0 (7.6, 8.5) Lactose: 5.66* 
Week 2-8 8.2 (7.9 – 8.5) 8.2 (8.0, 8.5) Lactose: 6.15 (5.93 – 6.32) 
1Data presented as mean (minimum – maximum) 
2Includes colostrum and preterm samples. Week 1 = 3 donors, week 2-8 = 5 donors, two of these donors provided samples in both week 1 and week 2-8. 
3Protein here represents true protein, which is bioavailable Nitrogen (total nitrogen – non protein nitrogen) x conversion factor (97, 193). True protein is corrected for so 
better represents the concentration of actual protein (155). The conversion factor used for phase one: 6.38 (155); for phase two: 6.25 (97) 
*Does not account for oligosaccharide concentrations (~2.1g/100ml and 1.7g/100ml for preterm values Gidrewicz et al. figures (9) therefore estimated total carbohydrate for 















Table 5.14: Comparison of measured pasteurised donor breast milk samples and audit references values for term milk 




Mean (95% CI) 
 
Gidrewicz et al. reference values used 
for Phase two (9) 
Energy (kcal/100ml) 67 (49 – 90) 67 (63, 72) 63 
Fat (g/100ml) 3.4 (1.4 – 5.7) 3.4 (2.9, 3.8) 3.4 
Protein
2
 (g/100ml) 0.8 (0.5 – 1.4) 0.8 (0.7, 0.9) 1.0 
Total Carbohydrate (g/100ml) 8.0 (7.3 – 8.5) 8.0 (7.9, 8.0) Lactose: 6.5* 
1Data presented as mean (minimum -maximum) 
2Protein here represents true protein, which is bioavailable Nitrogen (total nitrogen – non protein nitrogen) x conversion factor (97, 193). True protein is corrected for so 
better represents the concentration of actual protein (155). The conversion factor used for phase one: 6.38 (155); for phase two: 6.25 (9) 







The present study used a human milk analyser to determine the nutrient composition of donor 
breast milk, the influence of pasteurisation and maternal characteristics on composition, and 
the impact donor breast milk had on the nutritional status of moderate to late preterm infants 
in the NICU at Christchurch Women’s Hospital.  
6.1 Effect of Holder pasteurisation on donor breast milk 
There was a small (≤3%) although statistically significant (p≤0.001) reduction in the energy, 
carbohydrate and fat concentrations of donor breast milk after Holder pasteurisation. There is 
some research which has indicated significant reductions in both energy (107) and fat (105-
108) concentrations following pasteurisation. For the current study, fat change was 2.8% post 
pasteurisation, which was a lesser change than that seen in other studies (change by 3.5% – 
8.9% (105-108)). However, the majority of research suggests Holder pasteurisation has no 
significant effect on energy (105, 110), fat (109, 111, 118, 140) or carbohydrate (lactose and 
oligosaccharide) concentrations (32, 106, 107, 109, 144, 145). In the current study, 
pasteurisation did not alter protein concentrations, which is accordance with the majority of 
studies (105, 109, 110, 139, 142, 143).  
6.2 Effect of donor characteristics on the composition of donor breast milk 
There was a small but statistically significant inverse association between the protein 
composition of pasteurised donor milk and lactation week of the donor (0.01g/100ml lower 
per week of lactation), and whether milk was preterm or term (term milk 0.2g/100ml lower 
than preterm). These findings are corroborated by other research (10-13, 75, 77, 78, 80). 
The gestational age of the donor’s infant had a small but statistically significant 
inverse association with total carbohydrate content (0.02g/100ml lower carbohydrate content 
per week of increased gestation). This is not in agreement with other research which indicates 
that lactose concentrations increase with increasing gestation (74-76). It is not known whether 





shown that the hind milk (the second stage of milk in a single feeding session) has a lower 
lactose concentration (14, 74, 82). The findings in the current study could potentially be 
explained if the donor milk provided by mothers whose babies were born closer to term was 
more likely to be hind milk – for instance if expression for donation occurred after their own 
baby was fed. Similarly, milk donated by parents of more preterm infants could have been 
collected independently of infant feeding (i.e. if the infant was fed bottles of expressed milk 
(137)), or following shorter breast feeds. 
There may also have been other factors such as maternal age, BMI, diet quality and 
mode of delivery, which may have had an influence on the nutrient composition of donor 
breast milk, as indicated by research findings (15-17, 81, 98, 99). These donor characteristics 
were not available as that would have required a more complex ethics process.  
6.3 Nutritional interventions and outcome differences between cohorts 
A positive sign for the presence of the milk bank is that over half of moderate to late preterm 
infants admitted to NICU in 2016 and 2017 were recipients of pasteurised donor breast milk, 
and that this increased between the two years (53% to 77%). The reasons for infants not 
receiving donor milk were, first, the availability of milk bank supplies at the time, and second, 
parents’ choice. Equipment failures (e.g. pasteuriser break down) also had an impact on 
supply of donor milk at times.  
The significant increase in exclusive breast milk feeding from 27% before (2013) to 
72% (2016/17) with donor milk availability, suggests that the presence of the human milk 
bank and the availability of pasteurised donor milk increased exclusive breast milk feeding in 
the Christchurch NICU, in the moderate to late preterm cohort. The majority of recipients 
only receive donor milk for the first few days after birth while their mother is expressing to 
build up her own sustainable supply. These findings of the current study support research that 
indicates that human milk banks and the use of donor milk do not displace a mother’s own 





with breastfeeding moderate to late preterm infants (45), with difficulties changing to a breast 
feeding after tube feeding (46). 
When donor milk was available (2016/17), all infants had breast milk as their first 
enteral feed (either donated or their mother’s), as well as once reaching 120ml/kg/day enteral 
feeds. There appeared to be a reduction in the number of infants requiring intravenous 
dextrose after birth (80% to 69%; p=0.169), and there was a significant increase in 
breastfeeding on discharge (21% to 40%). These findings indicate that the use of pasteurised 
donor milk in the NICU allowed improvements in nutritional status for moderate to late 
preterm infants. This confirms current research indicating that infant formula use is reduced 
particularly in the first two weeks of life with the use of donor milk (19, 24, 25), and can 
increase discharge breastfeeding rates (26).  
There may of course have been other factors which influenced exclusivity of breast 
milk feeding and an increase in breastfeeding on discharge, other than solely the presence of 
donor milk. One example is improved lactation support for mothers in 2016/17, for increasing 
their own milk supply throughout the NICU stay and to continue breastfeeding after 
discharge. Research has indicated that milk expression support increases exclusive 
breastfeeding after discharge (45, 49, 50). The current study indicated that donor milk 
recipients had less additives to breast milk, but there could also be other factors contributing 
to the reduction in fortification, such as a policy change in the NICU during this time. 
6.4 Differences in energy and macronutrient intakes and growth  
The higher energy and fat intakes of donor milk recipients for week one demonstrates that the 
availability of pasteurised donor milk led to higher nutrient intakes for these infants by 
allowing earlier enteral feeds of donor milk. They did, however, have a 0.2g/kg lower protein 
intake compared to infants in the 2013 cohort. These differences are very small, so although 
statistically significant may not be clinically significant. One reason for the lower apparent 
protein intake could be a mature term milk value used to calculate intakes for pasteurised 





(81). Also, fortification was less likely to occur during week one of life, with the median day 
for 2013 being day 10 and for 2016/17 day 8. This fortification timing is similar to findings 
from other studies (194). 
Nutrient intakes for week two until discharge indicate significant differences between 
cohorts for energy and all macronutrients, with donor milk recipients having a lower mean 
daily intake of fat and protein (both 0.2g/kg), carbohydrate (0.7g/kg) and energy (5.5kcal/kg), 
than infants in 2013. This is a unexpected finding, but although statistically significant may 
not be important clinically. This may not be related to the fact these infants were donor milk 
recipients, as generally beyond week one and two, very few babies continue having donor 
milk. Also, breast milk reference values were used for these calculations so actual nutrient 
intakes could have been different. In addition, the later cohort overall had less additives, so 
the lower intakes could be due to the lower fortification rates. Although lower rates of 
fortification may have been the cause of lower nutrient intakes for 2016/17 infants, the data 
suggests there may have been small (although not statistically significant) improvements for 
this cohort for growth. This is indicated by the mean (SD) discharge weight and length z 
scores for the 2013 and 2016/17 infants: -1.01 (0.74) vs -0.88 (1.04) and -0.47 (0.86) vs -0.29 
(0.97) respectively. 
6.4.1 Comparison of nutrient intakes to ESPGHAN guidelines 
As previously discussed in Chapter two, ESPGHAN has guidelines for preterm infants up to 
1800g (66). In this study they would be appropriate for just 11 infants (~16%) in the 2013 
cohort and 14 infants (~20%) in the 2016/17 cohort. As indicated in Table 6.1 below, when 
comparing the ESPGHAN guidelines to the mean figures for week two until discharge, the 
mean energy for the 2016/17 cohort was just below the guidelines, and for both cohorts, mean 
protein and carbohydrate intakes were below the guidelines. Infants who are small for 
gestational age or of low birth weight may have higher requirements particularly for energy 
and protein intakes (66). This, therefore, would suggest that the nutrient requirements for 





guidelines. This aligns with the adequate intake (AI) for protein set for term infants (0-6 
months) of 1.43g/kg/day (195), which is much lower than ESPGHAN preterm requirements 
(3.5 – 4.0g/kg/day). Therefore, the large majority of moderate to late preterm infants in this 
study, who were larger than 1800g (80 – 84% for both cohorts), may have met their required 
nutrient and energy intakes, but it is also possible that their intakes were insufficient. 
Unfortunately, there are currently no guidelines for the nutritional requirements of moderate 
to late preterm infants to compare these findings to.  
Table 6.1: ESPGHAN guidelines compared to ‘week two until discharge’ mean nutrient 
intake for both cohorts 
Nutrient ESPGHAN guidelines (66) 2013  2016/17  
Energy (kcal/kg/day) 110 – 135  114 109* 
Protein (g/kg/day) 3.5 – 4.0  2.4* 2.2* 
Fat (g/kg/day) 4.8 – 6.6 5.9 5.7 
Carbohydrate (g/kg/day) 11.6 – 13.2 11.1* 10.5* 
*Indicates value lower than ESPGHAN guidelines 
6.5 Comparison between phase one samples and phase two reference values 
The phase two analyses of nutrient intake had to be carried out in parallel with the phase one 
analysis of donor milk composition, due to the time constraints of a MDiet thesis. It is 
therefore important to compare the analysed donor breast milk composition from phase one 
with the reference values used in phase two. This comparison indicates large differences for 
preterm milk composition. This may be because of differences in sample size, with phase one 
measured samples for 8 donor mothers, compared to the reference values which were from 
817 mothers (97). This larger sample size in the reference value study would be more 
representative of the population mean (182). For the term figures however, measurements 
were relatively similar, even given the sample size difference (24 term donor mothers vs 2299 
mothers for the reference data (9)).  
The difference between the analysed values and the reference values highlights a 
problem for clinical settings. If actual donor breast milk values are not known and reference 





makeup of the milk, leading to inaccurate fortification. Overfeeding for increasing growth 
may increase the risk of childhood obesity (63-65), and underfeeding may cause poor growth. 
Individualised fortification reduces this long-term risk by matching an infants’ actual 
macronutrient requirements to the analysed milk composition (171). Being able to accurately 
measure the composition of donated breast milk from the Human Milk Bank with a human 
milk analyser, is vital for achieving this.  
6.4 Strengths and Limitations 
A major strength of this study was that it is the first study in New Zealand to use a human 
milk analyser to determine donor breast milk composition. Another strength is that daily 
nutrition data and macronutrient intakes were recorded and calculated, so that a comparison of 
two-year groups could show the impact pasteurised donor milk had on the nutritional status of 
moderate to late preterm infants. 
There are a number of limitations to this study. First, the sample sizes for both phases 
were small. These small sample sizes are likely to have impacted on the ability of the study to 
find statistically significant differences (196). The study however was bound by the current 
supply of donor milk, pasteurisation procedures, and the short study timeframe. Second, it is 
important to note that the regression was based on a linear model, but this data may not be 
linear so a non-linear model may have been more appropriate – this would be a potential 
avenue for future research. Third, only infants who were recipients of donor milk were 
included in the 2016/17 cohort, so there was no comparison to those infants who did not get 
donor milk. A study that was longer than a MDiet would allow inclusion of all infants. Lastly, 
the milk feed volumes for demand breastfeeding were estimated (using the prescribed 
volume) in phase two, and median nutrient intakes were estimated. This has a number of 
possible consequences: as daily weight measurements were not taken, g/kg/day is just a best 
estimate for infants’ nutrient intake (i.e. intake of each day could not be adjusted for exact 
weight that day as weight was only measured every approximately 4 days); the median 





intakes (due to fortification) because the median excludes extreme values; and mean nutrient 
intakes may not be an accurate representation of the actual intakes of the infants (the 
reference values used may have underestimated the actual nutrient intake from both expressed 
preterm milk and donor milk, given that phase one suggested that preterm milk may provide 
more energy, fat and carbohydrate than is reflected in the reference values used). 
6.5 Conclusions and future research 
The presence of the Human Milk Bank and pasteurised donor milk in Christchurch NICU, 
correlates with and may be responsible for improved aspects of moderate to late preterm 
infants’ nutritional status, particularly by increasing exclusivity of breast milk feeding during 
NICU stay, discharge breast feeding rates and energy and fat intakes for the first week of life. 
There is a need for the development of guidelines for the nutritional requirements of moderate 
to late preterm infants. There is current ongoing New Zealand research (197) looking at 
approaches for moderate to late preterm infants’ nutrition (guided by the StRoNNG checklist 
(39)) to provide evidence for feeding practice guidance in this gestational age group.  
The Candidate proposes the following future research for Christchurch NICU from 
these results: a prospective study using phase one results to further categorise milk into 
nutrient density groups by specific clinical criteria relevant to Christchurch NICU practice. 
This will guide the implementation of individualised fortification procedures based on the 
nutrient composition of donor milk, to further improve the nutritional and growth outcomes of 
preterm infants; an observational milk analysis study over a longer time period with a larger 
sample size, extending the maternal characteristics collected to include maternal age, BMI, 
and mode of delivery to see the potential impact of these on nutrient composition; and a larger 
all-inclusive audit for moderate to late preterm infants which includes all infants, whether or 
not they were donor milk recipients, and specifically looking at infants exclusively breast fed 









7 Application of Research to Dietetic Practice 
 
The present study has highlighted the importance of human milk banks and pasteurised donor 
breast milk for preterm infants in Neonatal Intensive Care Units (NICUs), with the 
availability of donor milk having an impact on the nutritional wellbeing of moderate to late 
preterm infants. These findings confirm the beneficial impact donor milk can have 
specifically for moderate to late preterm infants, as there is currently limited research on the 
outcomes associated with having a milk bank. A vision of the Christchurch NICU service is 
for all preterm infants to have breast milk to minimise the risk of complications, and to 
provide other NICUs with assistance with the development of human milk banks.  
The overall goal of neonatal dietitians is to provide effective nutritional care for 
infants in the NICU through thorough assessment, intervention, monitoring and evaluation 
(187). The current study suggests that classification of term and preterm pasteurised donor 
milk samples into various nutrient density categories, using a human milk analyser, could 
improve the nutritional labelling of donor milk.  
One role of neonatal dietitians is to calculate an infant’s recommended requirements 
for energy and macronutrients per kg/day and compare this to actual intakes (187). If a 
particular infant is a donor milk recipient, a dietitian could work with the nursing and medical 
clinical staff, to choose the best nutrient profile fit from the donor milk samples available if 
they have been categorised. This may additionally mean if a high nutrient profile milk can be 
given to better match an infant’s nutrient requirements, this potentially could mean 
fortification is not required, or that the amount of fortifier needed could be reduced. Moderate 
to late preterm infants who will benefit the most from an individualised fortification approach 
are either long term NICU recipients of donor milk or those who are small for gestational age.  
At a higher level, neonatal dietitians are responsible for the development and 
implementation of nutrition guidelines, which guide all health professionals in the NICU with 
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Table 9.1: ESPGHAN Guidelines for enteral feeding for 
preterm infants up to 1800g (66) 
Nutrient Per kg/day 
Fluid, ml 135 – 200  
Energy, kcal 110 – 135 
Protein, g [<1 kg body weight] 4.0 – 4.5  
Protein, g [1-1.8 kg body weight] 3.5 – 4.0 
Lipids, g (of which MCT <40%) 4.8 – 6.6 
- Linolenic acid, mg 385 – 1540 
- a- linolenic acid, mg >55 
- DHA, mg 12 – 30 
- AA, mg 18 – 42  
Carbohydrate, g 11.6 – 13.2 
Sodium, mg 69 – 115 
Potassium, mg 66 – 132 
Chloride, mg 105 – 177 
Calcium salt, mg 120 – 140 
Phosphate, mg 60 – 90 
Magnesium, mg 8 – 15 
Iron, mg 2 – 3 
Zinc, mg 1.1 – 2.0 
Copper, µg 100 – 132 
Selenium, µg 5 – 10 
Manganese, µg £27.5 
Fluoride, µg 1.5 – 60 
Iodine, µg 11 – 55 
Chromium, ng 30 – 1230 
Molybdenum, µg 0.3 – 5 
Thiamin, µg 140 – 300 
Riboflavin, µg 200 – 400 
Niacin, µg 380 – 5500 
Pantothenic acid, mg 0.33 – 2.1 
Pyridoxine, µg 45 – 300 
Cobalamin, µg 0.1 – 0.77 
Folic acid, µg 35 – 100 
L-ascorbic acid, mg 11 – 46 
Biotin, µg 1.7 – 16.5 
Vitamin A, µg RE [1µg ~3.33 IU] 400 – 1000 
Vitamin D, IU/day 800 – 1000 
Vitamin E, mg [a-tocopherol 
equivalents] 
2.2 – 11 
Vitamin K1, µg 4.4 – 28 
Choline, mg 8 – 55 





Appendix B: High temperature short time (HTST) and High-Pressure Processing: two 
alternate pasteurisation methods 
 
 
Two alternate pasteurisation methods which have been adapted recently for human milk are: 
High temperature short time (HTST), and High-Pressure Processing.  
High temperature short time (HTST) is a method of thermal processing where 
products are exposed to 72oC or 87oC for up to 15 seconds, used for the elimination of 
pathogens from milk in the dairy industry (129, 139, 198-200).  
High Pressure Processing is used by food production companies (131) as an alternate 
method to thermal pasteurisation (30). At refrigeration temperatures, it involves treatment at a 
variety of high pressures for various time frames (between 100 – 1000 MPa where 100MPa 
represents 1000 times atmospheric pressure (201)). Both alternate pasteurisation methods are 
effective in the destruction of pathogenic activity similar to Holder pasteurisation (131, 139, 
198).  
There is limited research in these areas on the composition effects on human breast milk, but 
research has found that compared to holder pasteurisation, high temperature short time 
(HTST) and high pressure processing methods have a less detrimental effect on the nutritional 



















Appendix C: Other processing effects on breast milk composition 
 
 
Table 9.2: Effect of freezing (-20 oC) on breast milk composition 
Component Effect (Significant reduction 
up to 6 months) 
No effect (between 3-8 
months) 
Energy (107) (152) 
Lactose (107)  (152)  
Protein  (152)  
Fat  
Total, triglycerides, free fatty 
acids, lipoprotein lipase 
(107, 111, 113)  (152)  
Vitamins 
Riboflavin, B6, biotin, C, B12, 
total pantothenic acid 
  
(148) 
Niacin, free pantothenic acid (B7) (148)  
Lactoferrin and Lysozyme  (151) 





Table 9.3: Other processing effects on breast milk composition 
Processing Effect/Component Reduction  
(significant/non significant) 
No effect 
Storage Time (24 hours) 
Protein Nitrogen   (116) 
Minerals (Sodium, Copper, Zinc)  (116) 
Lactoferrin  (116) 
Lysozyme  (116) 
Storage Temperature (4oC / 37oC) 
Protein Nitrogen (4oC) (204)  
Vitamin C (4oC) (204)  
Ultrasonic Homogenisation 
Fat   (101) 
Vitamins (A, D, E, K)  (101) 
Tube feeding 
Vitamin C (44%) (116)  
Vitamin B6 (19%) (116)  
Fat (129)  
Phototherapy 
Vitamin C (53%) (116)  
Vitamin B6 (17%) (116)  
Microwave Thawing 








A 24-hour storage time was shown to have no effect on measured components (116). 
Temperature, tube feeding, light and microwave thawing was seen to effect vitamin C the 
most (116, 204). Thawing milk samples in a microwave potentially could lead to layer 
separation, plus the dangers of heating the milk too high, putting the feeding infant at risk 
(129). Microwaving also affects anti-infective properties, which worsens with higher 
temperatures (129). Heating milk resulted in a significant loss of polyunsaturated fats (higher 
than both monounsaturated or saturated (112)).   
 
Table 9.4: The effect of container type on breast milk composition 
Component Polyethylene Bags Pyrex Glass Polypropylene containers 
Protein Nitrogen  O (116) O (116) 
Vitamins (A, D, E, B2, B6, 
B12, folacin) 
 O (116) O (116) 
Minerals (Sodium, Copper, 
Zinc) 
 O (116) O (116) 
Immunoglobulins (IgA, sIgA) |   (129, 205) O (205) O (205) 
Lactoferrin O (205) |   (205) |   (205) 
Lysozyme O (205) |   (205) |   (205) 
Leukocytes  |   (116, 129)  
Key: O; no effect, |; reduction 
 
 
Conclusions from research cited above indicates that rigid polypropylene plastic containers 
are thought to be the best for use and for the preservation of milk composition (116), although 
there has been documented reduction in lactoferrin and lysozyme (205). In comparison, 
polyethylene bags are difficult to seal; can easily leak and immunoglobulin content is 
reduced, so therefore are not recommended (129, 137, 205), the same goes with glass bottles, 























































Table 9.5: Studies looking at the analysis of human milk against reference methods 
Study Analyser used Reference standards used Main findings Conclusions drawn 
Menjo et al 
2009 (153) 
MIR HMA (Miris) 
Unhomogenised 
milk 
Modified Folch method (Fat), 
Kjeldahl method (total nitrogen 
plus conversion factor 6.25 for 
protein*), High-performance 
liquid chromatography (Lactose) 
 
*Kjeldahl method - accurate 
indirect measure of protein 
measuring total nitrogen (TN) and 
non-protein nitrogen (NPN) (97) 
[TN – NPN] x 6.25 = true protein 
(159, 206) 
 
Reliable results of the HMA for protein, fat and lactose. 
 
Diluted milk with distilled water to see if reduced volume 
could be used:  
For lactose – showed significant difference for diluted and 
undiluted samples 
For fat and protein – dilution up to four times was enabled, 
meaning overall analysed volume reduced from 2ml to 
0.5ml.  
 
1ml of breast milk allows for accurate 
protein analysis by HMA, but diluted 
milk in HMA overestimates lactose 
content. 
 
Casadio et al 
2010 (154) 
MIR HMA (Miris) 
Ultrasonic 
homogenisation 
Esterified fatty acid (EFA) 
method (Fat), modified Bradford 
method and Kjeldahl (protein), 
Enzymatic spectroscopic method 
(Lactose) 
Factory calibrants of HMA: Röse-
Gottlieb method (Fat), Kjeldahl 
method (total nitrogen plus 
conversion 6.38 for protein), 
High-performance liquid 
chromatography (Lactose) 
Small but significant differences between HMA and 
reference methods.  
HMA compared to reference standards: higher fat, higher 
protein and lower lactose. 
 
Low lactose: HMA method measures lactose directly, while 
the reference method measures free lactose. Overestimation 
of the lab value could have occurred as oligosaccharides 
have terminal lactose ends, which could have been included 
in the concentration counted. 
Differences between the HMA and 
reference methods were expected due 
to the difference in standards chosen.  
 
Software updated since Menjo et al 
(153), to enable larger calibration 






MIR HMA (Miris) 
Ultrasonic 
homogenisation 
Gerber method (Fat), Bradford 
method (Protein), Chloramine-T 
method (Lactose) 
Significant differences between content from HMA analysis 
and laboratory measures.  
HMA compared to reference standards: higher for fat, lower 
for protein and lactose.  
Good correlation of all macronutrients indicating differences 




Difference between HMA and 
reference measures.  
Differences could be rectified by 













Mojonnier method (fat), Kjeldahl 
method (plus conversion of 6.25 
for protein), High Performance 
Liquid Chromatography (lactose) 
Very accurate in measuring protein content -which is the 
most needed nutrient measured.  
Agreement between analysis and reference methods high for 
fat and protein, while moderate for energy and lactose.  
Lactose measured higher – represents hidden 
oligosaccharides measured. 
Overestimation of energy – thought that HMA shouldn’t be 
used for energy measures. 
Difference between term and preterm milk samples not 
significantly different 
Used reference methods for the ‘gold 
standard’  
Able to accurately use 1ml samples 
(diluted to 10ml) 
Fusch et al 
2015 (157) 
MIR HMA (Miris) 





Mojonnier method (Fat), 





Near IR: Precise but inaccurate for protein and fat 
MIR: Precise and accurate for protein and fat 
Both Near IR and MIR: Imprecise and inaccurate for lactose 
Inability to precisely and accurately measure lactose may be 
due to oligosaccharide concentrations. 
Recalibration of HMA using a 
extended data set could improve fat 
and protein measures but still may 
not improve lactose readings.  
Billard et al 
2016 (40) 




Bligh and Dyer (Fat), Bradford 
and kjeldahl methods 
(protein/nitrogen), orcinol method 
(lactose) 
 
The fractionation of protein and fat from milk 
- Centrifugation into cream and protein phase enlarging 
range of fat to be assessed 
- Separating protein to mix with non-protein phase 
enlarging range for analysis.  
Regression lines formed comparing HMA to reference 
methods  
Regression lines which yielded 
coefficients could be used in the 
calibration of HMA devices. 
Zhu et al 
2017 (207) 





Kjeldahl (total nitrogen plus 
conversion factor 6.25 to protein), 
high-pH anion exchange 
chromatography (Lactose) 
High correlation between HMA and references for protein 
and fat. 
HMA compared to reference standards: higher for fat, lower 
for protein, no correlation of lactose 
 
No lactose correlation may be due to 
oligosaccharides not being accounted 
for 
Parat et al 
2017 (158) 




Mojonnier assay (Fat), Kjeldahl 
(protein), High Performance 
Liquid Chromatography (Lactose) 
Good comparison of protein and fat to lab values. Least 
accurate was lactose due to oligosaccharides not being 
accounted for.  
 




Appendix E: Further detailed processes of the Human Milk Bank 
 
 
Donors of human milk are recruited from the community or NICU. There is a two-stage 
process for screening potential donors: the first is the exclusion of donors on the basis of a 
health screening questionnaire before bloods are taken; the second based on investigations if 
health questionnaire is passed.  
All raw donor breast milk is stored in the ‘red’ freezer for up to six months prior to 
pasteurisation. Raw milk is thawed for a maximum of 24 hours at 2 – 6°C before 
pasteurisation. A sample of raw milk from each batch are routinely sent for microbial testing. 
The batch expiry date is either six months past the earliest expression date or three months 
post pasteurisation (decided by the earlier date). After milk is pooled as per processes 
discussed in Chapter 4 Section 4.2.1, Holder pasteurisation is performed, where milk is held 
in a water bath at 62.5°C for 30 minutes; and then is rapidly cooled down to 10°C. Samples of 
pasteurised milk are sent for microbial testing every 10 runs of pasteurisation or routinely 
after systems change. All pasteurised milk is transferred and stored in the ‘yellow’ freezer 
until microbial results are available. If milk is cleared, it is transferred to the ‘green’ freezer 
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Nutritional analysis of donor human milk. 
INFORMATION SHEET FOR   
Mothers Donating to the Milk Bank 
We are currently conducting research to develop our understanding of the nutritional contents 
of donated human milk before and after pasteurisation.  
 
What is the Aim of the Project? 
Thank you for being one of our donors to the Christchurch Human Milk Bank which was 
established in 2014. We have recently purchased some equipment (MIRIS Analyser) that 
allows us to analyse the nutritional contents of human milk. Our aim is to quantify the amount 
of protein, carbohydrate, fat and energy before and after the milk has been pasteurised.  
 
It is hoped that this will provide us with information about how we should supplement 
pasteurised donated milk in our preterm population. This information will aid us in designing 
a more detailed research study to look at more individual ways of supplementing pasteurised 
donated milk in our preterm population. 
 
What Types of Participants are being sought? 
We need to test human milk that has been donated by women that have had babies both at 
term or preterm and whose babies are between 1 day and 6 months old.  
 
What will Participants be asked to do? 
Women who donate their milk to the milk bank will not be identifiable to the research student 
and will not be asked to do any more than they are already doing. 
 
What Information will be collected and what use will be made of it? 
The data that is being collected refers to the nutritional data of the donated breastmilk that is 
already being used in the Milk Bank. At the end of the study the research student will be told 
the following: 
• Gestation of baby of donor mother 
• Time since delivery of baby of donor mother 
 The data will be analysed and any relationship of the gestation of delivery and time from 
delivery will be plotted and compared to the data published by others. We will be happy to 
share the results with women who donate to the Milk Bank but will not be able to feedback 
their own individual results. The only people who will have access to the identity of the donor 
mother will be the Milk Bank Staff and they will not be part of the research team. 
 
Can Participants opt out of the project? 
If you do not want your milk included in this research then please let the Milk Manager 
(Anthea Franks) know and she will ensure that your milk is not analysed. 
 
What if Participants have any Questions? 
If you have any questions at all then please do not hesitate to contact Maggie Meeks 
(supervisor of project) on maggie.meeks@cdhb.health.nz 
 
“This study has been approved by the University of Otago Human Ethics Committee (Health).If you have any concerns about 
the ethical conduct of the research you may contact the Committee through the Human Ethics Committee Administrator (ph 64-
3-479 8256 or gary.witte@otago.ac.nz). Any issues you raise will be treated in confidence and investigated and you will be 






































































































HMA set up prior to milk analysis 
After the HMA was turned on, up to 30 minutes is to be allowed for system to warm up prior 
to use (takes only approximately 10 minutes). Turn on the Miris ultrasonic processer and set 
to 75% amplitude as per manufacturer’s instructions (185). Time is set dependant on 
millilitres of milk (1.5sec/ml).  For a pictorial illustration of the entire analysis process, refer 
to Figure 9.2. Before analysis of milk samples, a zero check needs to be performed, as well as 




were warmed to 40°C in a water bath, as all liquids passing through the HMA must be 
warmed to 35 – 40°C beforehand (155). 
Miris Check: Under ‘analysis’, 3ml of Miris Check was injected into the HMA. This 
is for zero-level adjustment and quality control. Another check was repeated if ‘adjustment 
necessary’. If ‘no adjustment necessary’, continue on to the calibration of the HMA (155). 
Calibration of HMA: Internal calibration of the HMA is based off reference 
methods: Rose-Gottlieb for fat, Kjeldahl for crude protein, and true protein and carbohydrate 
calculated by difference (155). The measuring range for macronutrients are: fat (0.6 – 
5.9g/100ml), crude protein (0.8 – 3g/100ml), true protein (0.6 – 2.4g/100ml), carbohydrate (4 
– 8g/100ml). The Miris calibration control kit consists of two varying concentrations of a 
standard solution (control 1 and 2), and is used as a daily control to validate the internal 
calibration of the HMA. Control 1 corresponds to average concentrations of the 
macronutrients in breast milk and levels of macronutrients in control 2 are closer to the higher 
end of the HMA measuring range (162). This is a new updated solution since January 29, 
2018 (161), and to the best of our knowledge, has not been used in published research to date. 
Calibration control 1 is first mixed by gentle inversion then homogenised by the ultrasonic 
processor for 12 seconds (1.5sec/ml), the 3mm probe wiped clean after each use. A 3ml 
sample was analysed and compared against reference values. Reference values for the 
calibration solutions are specific to the HMA’s serial number (Table 9.6). Calibration control 
2 should be analysed following the same process as control 1, if results of control 1 were 
within range. If both controls are in range, continue onto the analysis of human milk samples.  
 
Table 9.6: Reference values for calibration control of HMA 
Nutrient Calibration Control 1 Calibration Control 2 
Fat 3.6 ± 0.2 6.7 ± 0.4 
Crude Protein 1.2 ± 0.2 2.6 ± 0.3 
Carbohydrate 7.8 ± 0.5 8.5 ± 0.6 







Miris Clean: Inject 5ml of cleaner solution into the blue inlet with pressure (until 
hearing a squeak) to ensure fluid is diverted through the front value. Next, inject 5ml into the 
same blue inlet but normal pressure. Change the waste tube over to the inlet. Inject 5ml of 
cleaner into the outlet with pressure so fluid is again diverted. Swap back the waste tube to the 
outlet if further analyses are to be performed. This should be followed by a Miris check.  
Separate syringes were used for check and cleaner and calibration control. Separate 
syringes per donor milk sample was preferred, however this was not able to be maintained for 
the entire duration of the study, due to problems with supply of the particular syringes. When 
this was the case, syringes were cleaned with distilled water between all samples including 
between pre and post. At the end of each session, the HMA was cleaned as per instructions 
with cleaner and distilled water, and the ultrasonic processor probe was wiped with cleaner, 
and polished by an emery cloth to prevent degradation (185). Syringes and small containers 
were washed in warm soapy water to be reused.  
Cleaning at the end of the day: Clean the HMA as per Miris clean instructions 
above, however leave waste tube on the blue inlet when finished process. Inject 5ml distilled 
water into the outlet with pressure to create fluid diversion. Put waste tube back on outlet and 
inject 5ml distilled water into the blue inlet with pressure. Repeat this with 5ml of water with 
normal pressure, and leave 0.5ml in the syringe. Leave the syringe in place for storage, or if 





























































Human milk analyser (HMA) on. 
Water bath filled, set to 40°C 
 
Miris Check: a zero check for adjustment 
Inject 3ml into HMA. Under ‘analysis’ 
press ‘check’ 
Calibration control 1: to 
validate the internal calibration  
- Gentle inversion of solution 
- Homogenise for 12 seconds 
(1.5/ml) 
- Inject 3ml sample 
- Press ‘start’ 
Put Miris check, cleaner and 
calibration solutions in water bath 
(all liquid passing through HMA 
needs to be between 35-40°C) 
 
 
Repeat steps of ‘control 1’ 
with calibration control 2 
 
At the end of the day:  
- Perform a clean as 
instructed 
- Leave waste tube on inlet 
- Inject 5ml distilled water 
into outlet with pressure 
- Change over waste tube to 
outlet 
- Inject 5ml distilled water 
into blue inlet with 
pressure 
- Repeat but with normal 
pressure 
- Leave 0.5ml left in syringe. 
Keep syringe attached for 
storage or remove and use 
black caps. 
 
Every 10th analysis, 
do a clean and check 
of the instrument. 
 
Clean:  
- Inject 5ml cleaner into 
blue inlet with pressure 
so fluid is diverted 
- Repeat but with normal 
pressure 
- Move waste tube to inlet 
- Inject 5ml cleaner into 
outlet with pressure 
- Change waste tube back 
to outlet 
Perform a check of the 
HMA as per above 
instructions. 
 
Ultrasonic Processor on 
Set to 75% amplitude 
 
Wait for water bath and 
HMA to warm up to 40°C 
~10-30 minutes 
 
If ‘no adjustment 




necessary’, inject 2ml of 
check into HMA. For 
further adjustment after 
this if necessary, inject 
1ml check (or HMA will 
need to be adjusted) 
 
Figure 9.2: Illustration of the overall process of using the human milk analyser (HMA) for measuring the 
macronutrient and energy composition of homogenised donor breast milk 
Abbreviations: HMA -Human Milk Analyser 
 
Compare to reference 
values unique to the HMA 
serial number 
If suitable, continue to 
control 2 
 
If not within range, repeat 
with another 3ml.  
 
Sample Analysis: 
- Warm up to 40°C 
- Inversion 10 times to mix 
- Measure 20ml with syringe into 
another container 
- Homogenise for 30 seconds (1.5/ml) 
- Inject 3ml for analysis. Press ‘start’ 
- Put sample back into water bath in 
between analyses 
- Record macronutrient and energy 
results 
Compare to reference values.  
If suitable, continue onto 
sample analysis. 
 
If not within range, repeat 

































27 donor mothers (providing 
one or more samples to the 
Human Milk Bank between 
July and September 2018) 
Total of n=63 batch samples 
available for use  
n=63 batch samples used for 
analysis as all current donors 
consented to participate 
63 pre pasteurisation samples 63 post pasteurisation samples  
Pasteurisation  
Total analysed n=126 pre and post pasteurisation samples per batch sample 
Each of these 126 samples was analysed in triplicate (n=378 analyses). The 
triplicate values were accounted for in the analyses (see section 4.2.6).  
 
For analysis of maternal characteristics:  
• Only post pasteurisation samples were used (n=58)* 
*5 batch samples excluded as 3 samples were from mother 
of twins and 2 were colostrum 
• 1 donor was excluded (n=26) due to mother of twins. 







































































































Crude protein concentration of pasteurised donor breast milk (g/100ml)
Colostrum Preterm Milk Term Milk
















































Figure 9.5: Categorising crude protein concentration of colostrum, preterm and term pasteurised 



























































Crude protein concentration of pasteurised 
donor breast milk (g/100ml) 
from mothers of male infants


















































Crude protein concentration of pasteurised 
donor breast milk (g/100ml) 
from mothers of female infants
Colostrum Preterm Milk Term Milk
Table 9.7: Multiple regression analysis of the impact of maternal characteristics on the crude protein 
concentration of post pasteurisation donor breast milk1 
Maternal Characteristic Change in crude protein concentration (g/100ml) for each unit change 
in characteristic 
 Unadjusted Adjusted2 
 B3 (95% CI) p B3 (95% CI) p 
Sex of donor’s infant (boys 
compared to girls) 
0.08 (-0.08, 0.24) 0.342 0.08 (-0.06, 0.22) 0.292 
Gestational age of donor’s 
infant, weeks 
-0.01 (-0.03, -0.0001) 0.042 0.00 (-0.01, 0.02) 0.791 
Lactation weeks of the 
donor, weeks 
-0.01 (-0.02, -0.01) <0.001 -0.01 (-0.02, -0.01) <0.001 
Term milk, compared to 
preterm 
-0.23 (-0.36, -0.10) 0.001 -0.23 (-0.36, -0.10) 0.001 
Bold indicates a statistically significant difference of p <0.05 
1Of the original 27 donors, one was excluded because she was a mother of twins (i.e. n=26). The final number of 
post pasteurisation samples used in the analysis was 58 following exclusion from the original 63 samples of the 3 
samples from the mother of twins, and the 2 colostrum samples. Each of these 58 samples was analysed in 
triplicate – see section 4.2.6 for an explanation of how these triplicates were included in the models. Multiple 
samples from the same donor were taken into account. 
2 Sex is adjusted for term milk and vice versa; gestational age and lactation stage are mutually adjusted for each 
other along with sex (i.e. term milk is not included in the same model as gestational age and lactation stage) 
3Coefficient shows change in g/100ml for each single unit change in the maternal characteristic – negative values 






















Figure 9.6: Comparison between crude protein concentration of pasteurised donor breast milk (g/100ml) for 
lactation stage and infant sex of donor mother 
 











































































Energy content of pasteurised donor breast 
milk (kcal/100ml)
from mothers of male infants








































































Energy content of pasteurised donor breast 
milk (kcal/100ml)
from mothers of female infants





















































Fat concentration of pasteurised donor 
breast milk (g/100ml) 
from mothers of male infants





















































Fat concentration of pasteurised donor 
breast milk (g/100ml) 
from mothers of female infants
Colostrum Preterm Milk Term Milk





















































Figure 9.7b: Comparison between fat concentration of pasteurised donor breast milk (g/100ml) for lactation 
stage and infant sex of donor mother 
 
*Total samples n=60. Exclusion of 3 preterm samples as mother of twins 
Figure 9.7a: Comparison between energy content of pasteurised donor breast milk (kcal/100ml) for 
lactation stage and infant sex of donor mother 
 


















































Protein1 concentration of pasteurised donor 
breast milk (g/100ml) 
from mothers of male infants















































Protein1 concentration of pasteurised donor 
breast milk (g/100ml)
from mothers of female infants
















































Total carbohydrate concentration of 
pasteurised donor breast milk (g/100ml)
from mothers of female infants
















































Total carbohydrate concentration of 
pasteurised donor breast milk (g/100ml) 
from mothers of male infants























Figure 9.7c: Comparison between protein concentration of pasteurised donor breast milk (g/100ml) for lactation 
stage and infant sex of donor mother 
 
*Total samples n=60. Exclusion of 3 preterm samples as mother of twins 
1Protein here represents true protein, which is bioavailable Nitrogen (total nitrogen – non protein nitrogen) x 


























Figure 9.7d: Comparison between total carbohydrate concentration of pasteurised donor breast milk 
(g/100ml) for lactation stage and infant sex of donor mother 
 




Appendix M: Abstracts submitted to the PSANZ 2019 Congress 
 
The effect of Holder pasteurisation and maternal characteristics on the composition of 
donated breast milk from the Human Milk Bank at Christchurch Women’s Hospital 
Lamb Rachael1, Little Helen2, Heath Anne-Louise3, Haszard Jillian3, Meeks Margaret4 
 
1Based at Christchurch Women’s Hospital, Masters of Dietetics student, Christchurch, New Zealand 
2Christchurch Hospital, Nutrition Services, Christchurch, New Zealand  
3Department of Human Nutrition University of Otago, Dunedin, New Zealand 
4Neonatal Intensive Care Unit, Christchurch Women’s Hospital, Christchurch, New Zealand 
Email: lamra743@student.otago.ac.nz  
 
Background: The presence of human milk banks allows use of pasteurised donated breast milk in 
Neonatal Intensive Care Units. Using a human milk analyser allows determination of the nutrient 
composition of donated breast milk which may help improve individualised fortification procedures. 
Methods: A total of 63 batch samples of breast milk were donated by 27 donor mothers to the Human 
Milk Bank, Christchurch Women’s Hospital. Unpasteurised and pasteurised (Holder pasteurisation – 
62.5°C for 30 minutes) samples of donated breast milk from the Human Milk Bank, Christchurch 
Women’s Hospital were homogenised, and energy and macronutrient content were analysed using a 
Miris Human Milk Analyser. Mixed effects regression models investigated the impact of three maternal 
characteristics on milk composition (gestational age and sex of the donor’s infant and lactation weeks 
of the donor or alternatively whether milk was term or preterm).  
Results: After Holder pasteurisation, there was a small (≤3%) but significant reduction (all p≤0.001) in 
the energy, fat and carbohydrate concentrations of milk. The energy and macronutrient content of 
pasteurised donor breast milk was highly variable. The protein concentration of pasteurised donor 
breast milk was significantly lower in term breast milk compared to preterm (-0.20g/100ml, p<0.001). 
Conclusions: The variance in donor breast milk indicates the importance of determining the nutrient 
composition of donated milk, for the benefit of improving individualised fortification procedures.  
 
The use of pasteurised donor breast milk in a Neonatal Intensive Care Unit improves aspects 
of moderate to late preterm infants’ nutritional status 
Lamb Rachael1, Meeks Margaret2, Heath Anne-Louise3, Haszard Jillian3, Little Helen4 
 
1Based at Christchurch Women’s Hospital, Masters of Dietetics student, Christchurch, New Zealand 
2Neonatal Intensive Care Unit, Christchurch Women’s Hospital, Christchurch, New Zealand  
3Department of Human Nutrition University of Otago, Dunedin, New Zealand 
4Christchurch Hospital, Nutrition Services, Christchurch, New Zealand  
Email: lamra743@student.otago.ac.nz 
 
Background: The presence of human milk banks allows the use of pasteurised donated breast milk in 
Neonatal Intensive Care Units (NICU) which has been shown to have benefits for preterm infant 
recipients. There is however limited research on the use of pasteurised donated breast milk with 
moderate to late (320 to 366 week) preterm infants as a NICU population.  
Methods: A retrospective comparison audit on moderate to late preterm infants from two cohorts of 71 
matched pairs by gestational age, sex and twin status. One cohort prior to (2013) and one after the 
opening of the Christchurch Women’s Hospital Human Milk Bank (2016/17).  
Results: There was a significant increase in the percentage of infants who were exclusively breast 
milk fed in the NICU, 27% to 72% (p<0.001) when donor breast milk was available. For donor milk 
recipients, the number receiving intravenous dextrose reduced, 80% to 69%, with a significant 
increase in discharge breastfeeding rates, 21% to 40% (p=0.014). The mean energy and fat intake for 
the first week after birth was significantly higher for those who had donor milk, 66 vs 71kcal/kg/day 
(p=0.051), and 2.8 vs 3.4g/kg/day (p<0.001) respectively. There was an improvement in the mean 
(SD) discharge z scores for weight (-1.01 (0.74) vs -0.88 (1.04)) and length (-0.47 (0.86) vs -0.29 
(0.97)) of donor milk recipients.  
Conclusions: These results suggest that the use of pasteurised donor breast milk in NICUs can 
significantly improve aspects of moderate to late preterm infants’ nutritional status.   
 
 
